

1 Title:

2 A dose-sensitive OGT-TET3 complex is necessary for normal Xist RNA distribution and
3 function

4

5 Authors:

6 Elizabeth Allene Martin^{1,2}, Jason C. Maynard³, Joel Hrit^{1,2}, Katherine Augspurger^{1,2},
7 Colette L. Picard^{4,5}, Suhua Feng^{4,5}, Steven E. Jacobsen^{4,5,6}, Alma L. Burlingame³,
8 Barbara Panning¹

9 ¹Department of Biochemistry and Biophysics, University of California San Francisco,
10 San Francisco, United States.

11 ²TETRAD Graduate Program, University of California San Francisco, San Francisco,
12 United States.

13 ³Department of Pharmaceutical Chemistry, University of University of California San
14 Francisco, San Francisco, United States.

15 ⁴Department of Molecular, Cell and Developmental Biology, University of California Los
16 Angeles, Los Angeles, CA 90095, USA.

17 ⁵Eli and Edyth Broad Center of Regenerative Medicine and Stem Cell Research,
18 University of California Los Angeles, Los Angeles, CA 90095, USA.

19 ⁶Howard Hughes Medical Institute (HHMI), University of California Los Angeles, Los
20 Angeles, CA 90095, USA.

21

22 Abstract:

23 Female (XX) mouse embryonic stem cells (mESCs) differ from their male (XY)
24 counterparts because they have lower levels of 5-methylcytosine (5mC) and 5-
25 hydroxymethylcytosine (5hmC). This difference in DNA modifications is a result of
26 having two X chromosomes (Xs), both of which are active at this developmental stage.
27 We identified an X-linked gene, *Ogt*, that controls levels of 5mC and 5hmC in mESCs.
28 OGT is a post-translational modification enzyme and we identified the 5-methylcytosine
29 dioxygenase TET3 as an OGT target that is differentially modified in XX and XY
30 mESCs. In addition to influencing 5mC and 5hmC abundance, OGT dose also controls
31 TET3 and OGT distribution. OGT and TET3 are predominantly nuclear in XX mESCs

32 and cytoplasmic in XY mESCs. Furthermore, these proteins are present in different
33 complexes in XX and XY mESCs. Mutational analysis revealed that TET3 determines
34 the XX-specific abundance of 5mC and 5hmC in mESCs. While TET3 null XX mESCs
35 exhibited modest changes in gene expression, there were substantial alterations upon
36 differentiation into epiblast-like cells (mEpiLCs). In addition, these TET3 null XX
37 mESCs did not undergo X-chromosome inactivation (XCI) when differentiated. These
38 data suggest that an X-dose sensitive complex containing OGT and TET3 regulates
39 cytosine modifications and XCI.

40

41 Introduction:

42 Female (XX) mouse embryonic stem cells (mESCs) exhibit lower global 5-methyl
43 cytosine (5mC) and 5-hydroxymethylcytosine (5hmC) than male (XY) mESCs (Habibi et
44 al., 2013, Zvetkova et al., 2005). These differences have been attributed to X-
45 chromosome (X) dosage, since XX mESCs that have lost one X (XO), display XY-like
46 cytosine modification levels (Zvetkova et al., 2005, Schulz et al., 2014). Both Xs are
47 active in XX mESCs and these cells therefore have a higher dose of X-linked transcripts
48 than XY or XO mESCs (Song et al., 2019), suggesting that one or more X-linked gene
49 products regulate 5mC and 5hmC levels. One X-linked gene implicated in regulation of
50 cytosine modifications is O-linked N-acetylglucosamine (O-GlcNAc) Transferase (OGT)
51 (Lewis et al., 2014).

52

53 OGT is the sole enzyme responsible for attaching a single O-linked GlcNAc sugar to
54 serine and threonine residues on thousands of nuclear, cytoplasmic, and mitochondrial
55 proteins (Haltiwanger et al., 1990; Hanover et al., 2012; Maynard et al., 2016). Like
56 phosphorylation, O-GlcNAcylation is a reversible modification that affects the function of
57 target proteins. OGT has been linked to regulation of cytosine modifications because it
58 stably interacts with and modifies the Ten-Eleven Translocation (TET) family of
59 enzymes (Vella et al., 2013; Deplus et al., 2013; Chen et al., 2013). The three TETs
60 (TET1, TET2, TET3) are dioxygenases that each oxidize 5mC to 5hmC. 5hmC is not
61 recognized by the maintenance DNA methyltransferase (DNMT1), resulting in passive
62 demethylation during replication (Parry et al., 2021). TETs also oxidize 5hmC to 5-

63 formylcytosine and 5-carboxylcytosine, which are substrates for base excision repair
64 (Tahiliani et al., 2009; Ito et al., 2010; Kriaucionis and Heintz, 2009; He et al., 2011; Ito
65 et al., 2011). Because these higher oxidized states are replaced by cytosine during
66 repair, TETs can also direct active demethylation that does not rely on DNA replication
67 (Ross et al., 2019; Parry et al., 2021).

68

69 OGT's interaction with and modification of TETs can stimulate TET activity (Hrit et al.,
70 2018) and can control TET nucleocytoplasmic distribution (Zhang et al., 2014),
71 providing two mechanisms by which this post-translational modification enzyme could
72 regulate TETs and thus cytosine modifications. To test whether OGT is one of the X-
73 linked proteins that regulates 5mC and 5hmC in mESCs, we manipulated OGT dose in
74 XX and XY mESCs and found that OGT abundance controls cytosine modifications. Our
75 search for OGT targets that are differentially modified revealed that TET3 is more
76 modified in XX than in XY mESCs. In addition, TET3 differs in abundance and
77 distribution and forms distinct complexes in these two cell types. OGT dose also
78 controls TET3 and OGT nucleocytoplasmic distribution. We found that in TET3 null XX
79 mESCs 5mC and 5hmC abundance is altered without notably affecting gene
80 expression. To investigate the developmental significance of TET3, we examined the
81 effects of this null mutation on the ability of cells to undergo X chromosome inactivation
82 (XCI), an epigenetic change that occurs when XX mESCs are differentiated into the
83 next developmental stage, epiblast-like (mEpiL) cells. The establishment of XCI is
84 characterized by the up-regulation of a non-coding RNA, Xist RNA, which remains in the
85 nucleus and 'coats' the X concomitant with silencing (Boeren et al., 2021). In TET3
86 mutant XX mEpiLCs, Xist RNA exhibits abnormal distribution and silencing defects.
87 These results link the activity of a dose-sensitive complex containing X and autosomal
88 proteins to regulation of cytosine modifications and XCI.

89

90 Materials and Methods:

91 Mouse embryonic stem cells (mESCs) and culture conditions

92 mESCs (Supplemental methods 1A) were routinely passaged by standard methods
93 using serum+LIF (mESC) media consisting of KO-DMEM, 10% FBS, 2 mM L-glutamine,

94 1X non-essential amino acids, 0.1 mM 2-mercaptoethanol and recombinant leukemia
95 inhibitory factor. Cells were also grown in 2i media consisting of N2B27 media
96 (DMEM/F12, neurobasal media, 2mM L-glutamine, 0.1mM 2-mercaptoethanol, 100X N2
97 supplement, 50X B27 supplement) and supplemented with 3mM CHIR99021, 1mM
98 PD0325901, and recombinant leukemia inhibitory factor. To achieve EpiLC
99 differentiation, tissue-culture dishes were incubated with Geltrex (Gibco) diluted in
100 DMEM/F12 media for 30 minutes and replaced with N2B27 media supplemented with
101 10ng/mL FGF2 and 20ng/mL Activin A (mEpiLC media). The cells were cultured in
102 mEpiLC media for five days, replacing the media every day.

103

104 CRISPR/Cas9 Gene Editing

105 XX WT/OGT-deg and XX-OGT-GFP mESCs were derived from LF2 XX mESCs using
106 homologous-directed repair CRISPR/Cas9 genome editing. A guide RNA to the OGT
107 3'UTR (Supplemental methods 1B) was cloned into the px459-Cas9-2A puromycin
108 plasmid using published protocols (Ran et al., 2013). Templates for homology directed
109 repair were amplified from gene blocks (IDT) (Supplemental methods 2-3). Plasmid and
110 template were co-transfected into LF2 mESCs using FuGENE HD (Promega) according
111 to the manufacturer's protocol. After two days, cells were selected with puromycin for
112 48 hours, then allowed to grow in antibiotic-free media. Cells were monitored for green
113 fluorescence and single fluorescent cells were isolated by FACS. All cell lines were
114 propagated from a single cell and correct insertion was confirmed by PCR genotyping
115 (Supplemental methods 3).

116

117 XX-TET3KO mESCs were derived from LF2 XX mESCs using non-homologous end
118 joining CRISPR/Cas9 genome editing. Two guide RNAs were selected approximately
119 700 base pairs apart in the first coding exon, exon 3, of *Tet3* (Supplemental methods
120 1B). They were individually cloned into the px458-Cas9-2A-GFP plasmid using
121 published protocols (Ran et al., 2013). Plasmids were co-transfected into LF2 mESCs
122 using FuGENE HD (Promega) according to the manufacturer's protocol. After two days,
123 single GFP-positive cells were isolated by FACS and placed into individual wells of 96-
124 well tissue-culture plates. All cell lines were propagated from a single cell and TET3

125 knockouts identified by immunoblotting. *Tet3* disruption was confirmed by sequencing of
126 each allele (Supplemental methods 3; Fig 4.-fig. sup. 1-3), which identified indels and
127 point mutations. Chromosome number of all cell types was determined by counting
128 metaphase spreads (LF2, E14, LF2-XO) or by G-banding (LF2, XX WT/OGT-deg lines,
129 XX-TET3KO lines).

130

131 DNA cytosine modification immunofluorescence staining

132 For mESCs, cell pellets were resuspended and incubated for 10min in 0.075 M KCl
133 hypotonic solution. After removing the hypotonic solution by centrifugation, a fixative
134 solution (3:1, methanol:glacial acetic acid) was added dropwise to the cell suspension.
135 Cells were collected, rinsed with fixative solution at least twice, and dropped onto glass
136 slides. For mEpiLCs, cells were cytopspun onto glass slides at 800rpm for 3 minutes and
137 then fixed in methanol:acetic acid (3:1) solution for 5 minutes and washed with PBST
138 (0.01% Tween in PBS) for 5 minutes.

139

140 To denature DNA, the fixed cells were washed twice with PBST and incubated in 1N
141 HCl at 37°C for 30 minutes. The HCl was neutralized in 100mM Tris pH 7.6 at room
142 temperature for 10 minutes, and then the cells were washed twice more with
143 PBST. The slides were blocked in 5% goat serum, 0.2% fish skin gelatin, and
144 0.2% Tween in PBS (IF blocking buffer) at room temperature for one hour. Primary
145 antibodies against 5mC and 5hmC (Supplemental methods 1C) were incubated on cells
146 for one hour at room temperature. Then cells were washed twice with PBST and
147 incubated with secondary antibodies (Jackson ImmunoResearch) for one hour at room
148 temperature. After incubation, slides were washed with PBST three times. On the
149 second wash, DAPI was added to the PBST. The cells were then mounted using
150 prolong gold antifade (Molecular Probes).

151

152 DNA cytosine modification fluorescent intensity image quantification

153 Nuclei were masked and pixel intensity determined using ImageJ. The pixel mean
154 intensity value was used to quantify fluorescent intensity inside each nucleus. 50 cells

155 were quantified per condition. Significance was determined by using the “paired two
156 samples for means” t-test.

157

158 Protein immunofluorescence staining

159 mESCs were cytopspun onto glass slides at 800rpm for 3 minutes and then fixed in 4%
160 paraformaldehyde for 10 minutes and washed with PBST. The slides were incubated in
161 IF blocking buffer at room temperature for one hour. Primary antibodies were incubated
162 on cells for one hour at room temperature (Supplemental methods 1C). Then cells were
163 washed twice with PBST and incubated with secondary antibodies (Jackson
164 Immunoresearch) for one hour at room temperature. After incubation, slides were
165 washed with PBST three times. On the second wash, DAPI was added to the
166 PBST. The cells were then mounted using prolong gold antifade (Molecular Probes).

167

168 Nuclei isolation

169 Cells were harvested, washed twice with cold PBS, and resuspended in nuclear
170 preparation buffer I (320 mM sucrose, 10 mM Tris (pH 8.0), 3 mM CaCl₂, 2 mM
171 Mg(OAc)₂, 0.1 mM EDTA, 0.1% Triton X-100, protease inhibitors, and phosphatase
172 inhibitors) and dounce-homogenized on ice until >95% of nuclei stained by Trypan blue.
173 Two volumes of nuclear preparation buffer II (2.0 M sucrose, Tris (pH 8.0), 5 mM
174 Mg(OAc)₂, 5 mM DTT, 20 μM Thiamet G, protease inhibitors, and phosphatase
175 inhibitors) were added to the nuclei suspension. Nuclei were pelleted by
176 ultracentrifugation at 130,000 × g at 4°C for 45 min. Pelleted nuclei were washed with
177 cold PBS and stored at -80°C.

178

179 Immunoblots

180 Cell pellets were lysed in ice-cold RIPA buffer (150mM sodium chloride, 1% NP-40,
181 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50mM Tris, pH 8.0, protease
182 inhibitors) for 20 minutes and centrifuged at 14,000 rpm for 10 minutes at 4°C. The
183 supernatant was decanted, and Pierce 660nm Protein Assay kit (Promega) was used
184 for quantification. Proteins were prepared using 4x Laemmli sample buffer and boiled
185 for 5 minutes at 100°C. Proteins were separated on a denaturing SDS-PAGE gel and

186 transferred to PVDF membrane. Membranes were blocked in PBST +5% nonfat dry milk
187 at room temp for 30 minutes or at 4°C overnight. Membranes were incubated in primary
188 antibodies (Supplemental methods 1C) for one hour at room temperature or at 4°C
189 overnight and then rinsed briefly with DI water twice and washed for 5 minutes in
190 PBST. Next, the membranes were incubated in HRP-conjugated secondary antibodies
191 (Bio-rad) for one hour at room temperature and then washed for 5 minutes in PBST,
192 three times. Blots were incubated with Pico Chemiluminescent Substrate
193 (ThermoFisher) and exposed to film in a dark room.

194

195 Sample Preparation for SILAC

196 LF2 (XX) and E14 (XY) mESCs were grown under standard conditions using DMEM for
197 SILAC, 10% dialyzed FBS, 2mM glutamine, 1X non-essential amino acids, 0.1mM b-
198 mercaptoethanol, and recombinant leukemia inhibitory factor. XX mESCs were grown
199 in light isotopes, L-Arginine-HCL and L-Lysine-HCL. XY mESCs were grown in heavy
200 isotopes, L-Lysine-2HCL (13C6, 15N2) and L-Arginine-HCL (13C6, 15N4)
201 supplemented with 200 mM proline to avoid arginine-to-proline conversion.
202 Cells were trypsinized, washed twice with cold PBS and then sonicated in 67 mM
203 ammonium bicarbonate containing 8M guanidine HCl, 8X Phosphatase Inhibitor
204 Cocktails II and III (Sigma-Aldrich), and 80 uM PUGNAc (Tocris Bioscience). Protein
205 concentrations were estimated with bicinchoninic acid protein assay (ThermoFisher
206 Scientific). Ten mgs of each lysate were combined, reduced for 1 h at 56°C with 2.55
207 mM TCEP and subsequently alkylated using 5 mM iodoacetamide for 45 min at room
208 temperature in the dark. Lysates were diluted to 1M guanidine HCl using 50 mM
209 ammonium bicarbonate, pH 8.0, and digested overnight at 37°C with sequencing grade
210 trypsin (ThermoFisher Scientific) at an enzyme to substrate ratio of 1:50 (w/w). Tryptic
211 peptides were acidified with formic acid (Sigma-Aldrich), desalted using a 35 cc C18
212 Sep-Pak SPE cartridge (Waters), and dried to completeness using a SpeedVac
213 concentrator (Thermo).

214

215

216

217 Lectin Weak Affinity Chromatography

218 Glycopeptides were enriched as described previously (Trinidad et al., 2012; Maynard et
219 al., 2020). Briefly, desalted tryptic peptides were resuspended in 1000 µl LWAC buffer
220 (100 mM Tris pH 7.5, 150 mM NaCl, 2 mM MgCl₂, 2 mM CaCl₂, 5% acetonitrile) and
221 100 µl was run over a 2.0 x 250-mm POROS-WGA column at 100 µl/min under isocratic
222 conditions with LWAC buffer and eluted with a 100-µl injection of 40 mM GlcNAc.
223 Glycopeptides were collected inline on a C18 column (Phenomenex). Enriched
224 glycopeptides from 10 initial rounds of LWAC were eluted with 50% acetonitrile, 0.1%
225 FA in a single 500-µl fraction, dried. LWAC enrichment was repeated for a total of three
226 steps.

227

228 Offline Fractionation

229 Glycopeptides were separated on a 1.0 × 100 mm Gemini 3µ C18 column
230 (Phenomenex). Peptides were loaded onto the column in 20 mM NH₄OCH₃, pH 10 and
231 subjected to a gradient from 1 to 21% 20 mM NH₄OCH₃, pH10 in 50% acetonitrile over
232 1.1 mL, up to 62% 20 mM NH₄OCH₃, pH10 in 50% acetonitrile over 5.4 mL with a flow
233 rate of 80 µL/min.

234

235 Mass Spectrometry Analysis

236 Glycopeptides were analyzed on an Orbitrap Fusion Lumos (Thermo Scientific)
237 equipped with a NanoAcquity UPLC (Waters). Peptides were fractionated on a 15 cm ×
238 75 µM ID 3 µM C18 EASY-Spray column using a linear gradient from 2% to 30%
239 solvent B over 65 min. Precursor ions were measured from 350 to 1800 m/z in the
240 Orbitrap analyzer (resolution: 120,000; AGC: 4.0e5). Each precursor ion (charged 2–8+)
241 was isolated in the quadrupole (selection window: 1.6 m/z; dynamic exclusion window:
242 30 s; MIPS Peptide filter enabled) and underwent EThcD fragmentation (Maximum
243 Injection Time: 250 ms, Supplemental Activation Collision Energy: 25%) measured in
244 the Orbitrap (resolution: 30,000; AGC; 5.04). The scan cycle was 3 s.

245

246 Peak lists for EThcD were extracted using Proteome Discoverer 2.2. EThcD peak lists
247 were filtered with MS-Filter, and only spectra containing a 204.0867 m/z peak

248 corresponding to the HexNAc oxonium ion were used for database searching. ETHcD
249 data were searched against mouse and bovine entries in the SwissProt protein
250 database downloaded on Sept 06, 2016, concatenated with a randomized sequence for
251 each entry (a total of 22,811 sequences searched) using Protein Prospector (v5.21.1).
252 Cleavage specificity was set as tryptic, allowing for two missed cleavages.
253 Carbamidomethylation of Cys was set as a constant modification. The required mass
254 accuracy was 10 ppm for precursor ions and 30 ppm for fragment ions. Variable
255 modifications are listed in Supplemental methods 4. Unambiguous PTMs were
256 determined using a minimum SLIP score of six, which corresponds to a 5% local false
257 localization rate (Baker et al., 2011). Modified peptides were identified with a peptide
258 false discovery rate of 1%. O-GlcNAc and O-GalNAc modifications were differentiated
259 based on known protein subcellular localization and HexNAc oxonium ion fragments
260 138/144 ratio (Halim et al., 2014; Maynard et al., 2020).

261

262 GFP co-immunoprecipitation

263 Cell pellets were lysed in ice-cold RIPA buffer supplemented with DNaseI and protease
264 inhibitors and placed on ice for 30 minutes, extensively pipetting the suspension every
265 10 minutes. The suspension was centrifuged at 17,000 rpm for 10 minutes at 4°C and
266 the supernatant lysate was decanted into a cold eppendorf tube with dilution buffer (10
267 mM Tris/Cl pH 7.5, 150 mM NaCl, 0.5 mM EDTA). The GFP-Trap dynabeads
268 (Chromotek) were equilibrated with wash buffer (10 mM Tris/Cl pH 7.5, 150 mM NaCl,
269 0.05 % NP-40, 0.5 mM EDTA) and the lysate was bound to the beads by rotating end-
270 over-end for one hour at 4°C. The beads were washed three times in wash buffer and
271 bound proteins were eluted by boiling in 2x Laemmli sample buffer.

272

273 Size Exclusion Column Chromatography

274 Nuclei were lysed in a high salt buffer (20mM Tris-HCl, pH 7.6, 300mM NaCl, 10%
275 glycerol, 0.2% (v/v) Igepal (Sigma-Aldrich, 630)) and were loaded on a Superose 6
276 10/30GL column (Amersham) and fractionated in high salt buffer. 0.5 mL fractions were
277 collected and concentrated into a smaller volume using a spin column-concentrator
278 (Pierce). Fractions were then analyzed via immunoblot.

279 RNA-seq

280 RNA was extracted using the direct-zol RNA miniprep kit (Zymo Research). Total RNA
281 was monitored for quality control using the Agilent Bioanalyzer Nano RNA chip and
282 Nanodrop absorbance ratios for 260/280nm and 260/230nm. Library construction was
283 performed according to the Illumina TruSeq Total RNA stranded protocol. The input
284 quantity for total RNA was 200ng and rRNA was depleted using ribo-zero rRNA gold
285 removal kit (human/mouse/rat). The rRNA depleted RNA was chemically fragmented
286 for three minutes. First strand synthesis used random primers and reverse
287 transcriptase to make cDNA. After second strand synthesis the ds cDNA was cleaned
288 using AMPure XP beads and the cDNA was end repaired and then the 3' ends were
289 adenylated. Illumina barcoded adapters were ligated on the ends and the adapter
290 ligated fragments were enriched by nine cycles of PCR. The resulting libraries were
291 validated by qPCR and sized by Agilent Bioanalyzer DNA high sensitivity chip. The
292 concentrations for the libraries were normalized and multiplexed together. The
293 multiplexed libraries were sequenced using paired end 100 cycles chemistry on the
294 NovaSeq 6000 with a depth of 50M reads per sample.

295 RNA-seq data analysis

296 Sequencing reads were analyzed for quality control using FASTQC(v. 0.11.2), then
297 trimmed using Trimmomatic(v.0.32) with Illumina TruSeq adapter sequences, PHRED
298 quality score 15 and minimum length 20 bases. The trimmed reads were aligned to the
299 reference genome with transcriptome annotation and post-processed using
300 Tophat2(v.2.0.12), Bowtie2(v.2.2.3), Samtools(v.0.1.19). Reads from the same samples
301 were combined. Expression levels were quantified both with FPKM (Fragment per
302 kilobase per million mapped reads) using Cufflinks(v. 2.1.1) and with raw counts using
303 HTSeq(v.0.6.1p1.). Differential analysis was performed using DESeq(v.1.18.0).

304

305 Whole Genome Bisulfite Sequencing (WGBS)

306 Genomic DNA was extracted using the Monarch Genomic DNA purification kit (New
307 England Biolabs). 400ng genomic DNA was used to construct whole-genome bisulfite
308 libraries. Briefly, DNA was sonicated by a Covaris S2 focused-ultrasonicator to ~200bp,
309 end repaired and adenylated using the Kapa DNA Hyper kit, and ligated to pre-

310 methylated Illumina TruSeq LT adapters. Adapter ligated DNA was treated by the
311 Qiagen Epitect bisulfite conversion kit. The bisulfite treated DNA was then amplified by
312 the Bionline MyTaq HS DNA polymerase to generate final libraries for sequencing.
313 Reads were sequenced 151x151bp paired-end on an Illumina NovaSeq 6000.

314

315 WGBS Analysis

316 Raw paired-end reads were filtered for poor quality and trimmed to remove poor quality
317 ends and adapter sequences using trim_galore (Krueger et al., 2019) v.0.5.0 with
318 options -q 25 --stringency 3. Trimmed pairs were aligned to the mouse genome version
319 GRCm38/mm10 using Bismark (Krueger et al., 2011) v.0.20.1 with options -L 22 -N 0 -l
320 0 -X 500, all other settings default. Uniquely mapping pairs were retained for analysis,
321 and were further filtered to remove likely unconverted reads (defined as 3 consecutive
322 unconverted Cs in the CHH context) using a custom script. PCR duplicates were
323 removed and per-position DNA methylation information was extracted using Bismark.

324

325 DMRs were identified using the method described in Pignatta et al., 2015. Briefly,
326 weighted average methylation at CG or non-CG sites with at least 5 coverage was
327 obtained over non-overlapping 1kb bins tiled genome-wide for each library. Libraries
328 were compared pairwise, for a total of 15 comparisons. For each comparison, all 1kb
329 windows containing at least 3 informative sites shared between both samples were
330 identified, and Fisher's exact test was used to test for significant differences in
331 methylation levels between the two samples. P-values were corrected for multiple
332 hypothesis testing using the Benjamini-Hochberg (Hochberg et al., 1995) method.
333 Windows with corrected $p < 0.01$ and a minimum difference of 35 (CG) or 10 (non-CG)
334 percentage points were considered DMRs.

335

336 Violin plots and smoothed scatterplots were plotted in R (R Core Team., 2017) v.3.5.1
337 using ggplot2 (Wickham et al., 2016) v.3.1.0 and smooth Scatter respectively.
338 Smoothed plots of DMR or feature density were obtained by counting the number of
339 DMRs/features over 50kb windows tiled genome-wide, then smoothing using the R
340 loess() function with span = 0.05 and plotting using ggplot2. Feature coverage was

341 obtained by calculating the fraction of bp out of 50kb covered by the feature in each
342 window. Smoothed plots of average methylation over chromosomes were obtained
343 similarly by averaging methylation over 50kb windows, smoothing and plotting as
344 described.

345

346 Major and minor satellite annotations were obtained from the UCSC table browser
347 RepeatMasker (Smit et al., 1996) tracks for mm10, annotated as GSAT_MM and
348 SYNREP_MM respectively. Average methylation over these regions was compared to
349 randomly shuffled regions 200 times to obtain an approximate p-value for the
350 significance of differences in methylation over the satellites relative to the rest of the
351 genome. Table of alignment statistics for WGBS libraries are in Supplemental methods
352 5. All custom scripts are available upon request.

353

354 RNA FISH

355 RNA FISH was performed using directly labeled double-stranded DNA probes, as
356 previously described (Mlynarczyk-Evans et al., 2006). Primers used to generate the Xist
357 probe are indicated in Supplemental methods 2A. COT-1 FISH was carried out using
358 labeled mouse COT-1 DNA (Invitrogen). For quantification, over 100 nuclei were
359 scored per experiment and significance was determined by using the “paired two
360 samples for means” t-test.

361

362 H3K27me3 IF and Xist RNA FISH combination

363 IF was carried out as previously described with the addition of 1mg/mL yeast tRNA
364 (Invitrogen) in the blocking buffer and then fixed in 2% PFA for 5 minutes. Xist RNA
365 FISH, as previously described, was immediately carried out.

366

367 Imaging

368 All imaging was done on an Olympus BX60 microscope using a 100X objective. Images
369 were collected with a Hamamatsu ORCA-ER digital camera using Micromanager
370 software.

371

372 Reproducibility and Rigor

373 All IF, immunoblots, co-IPs, and FISH are representative of at least three independent
374 biological replicates (experiments carried out on different days with a different batch of
375 mESCs or mEpiLCs). For targeted mESC lines, two-three independently derived lines
376 for each genotype were assayed in at least three biological replicates. For size
377 exclusion column chromatography assay, two biological replicates were carried out. For
378 RNA-seq, three technical replicates of XX and three independently-derived XX-TET3KO
379 mESCs and mEpiLCs were analyzed. For WGBS, three technical replicates of XX and
380 three independently-derived XX-TET3KO mESCs were analyzed. We define an outlier
381 as a result in which all the controls gave the expected outcome, but the experimental
382 sample yielded an outcome different from other biological or technical replicates. There
383 were no outliers or exclusions.

384 Data Availability

385 Annotated spectra, peak lists, and the table of results for the TET1, TET2, and TET3 O-
386 GlcNAcylated peptides can be viewed and downloaded from MS-Viewer with the
387 keyword pfsmorbazl.

388 ([https://msviewer.ucsf.edu:443/prospector/cgibin/mssearch.cgi?report_title=MSViewer&](https://msviewer.ucsf.edu:443/prospector/cgibin/mssearch.cgi?report_title=MSViewer&search_key=pfsmorbazl&search_name=msviewer)
389 [search_key=pfsmorbazl&search_name=msviewer](https://msviewer.ucsf.edu:443/prospector/cgibin/mssearch.cgi?report_title=MSViewer&search_key=pfsmorbazl&search_name=msviewer)) (Baker et al., 2014).

390 RNA-seq data has been uploaded to GEO under accession GSE171847.

391 WGBS data has been uploaded to GEO under accession GSE178378.

392

393 Results:

394 **OGT Dose Controls Cytosine Modifications**

395 5mC and 5hmC are lower in XX mESCs than in XY mESCs when measured using
396 assays that do not distinguish between these two modifications (Zvetcova et al., 2005;
397 Schulz et al., 2014; Choi et al., 2017). This difference could be attributed to X-copy
398 number, since XO mESCs exhibit XY levels of 5mC and 5hmC using these assays
399 (Zvetcova et al., 2005; Schulz et al., 2014). Quantitation of 5mC and of 5hmC revealed
400 a 4-fold decrease in each of these modifications in XX mESCs relative to XY mESCs
401 (Habibi et al., 2013). To determine the effects of losing one X on 5mC and 5hmC

402 abundance and distribution, we used immunofluorescence staining (IF) to compare
403 these modifications in LF2 (XX), E14 (XY), and an XO line derived from LF2 (XO). 5mC
404 (Fig. 1A) and 5hmC (Fig. 1B) levels in XY and XO cells were higher than in XX cells in
405 serum and LIF-containing mESC media and in 2i media (Fig. 1-fig. sup. 1A-B). 5mC IF
406 also revealed an additional difference between XX and XY/XO mESCs. In XY and XO
407 mESCs nearly all cells showed enrichment of 5mC on pericentromeric heterochromatin,
408 marked by intense staining with DNA dye DAPI. In contrast, in XX mESCs
409 approximately 65% of cells showed 5mC enrichment on pericentromeric
410 heterochromatin, while the remaining 35% of cells showed little or no pericentromeric
411 heterochromatin enrichment (Fig.1-fig. sup. 1C). These results raised the question of
412 why cytosine modifications in mESCs are dependent on X-copy number.

413
414 mESCs exist in a developmental state prior to the onset of dosage compensation by
415 XCI. Because XX mESCs have two active Xs, the increased dose of an X-linked
416 regulator or regulators of cytosine modifications could specify the XX-specific
417 abundance of 5mC and 5hmC. Since none of the enzymes involved in addition or
418 turnover of 5mC are encoded on the X, an X-linked regulator of DNMTs or TETs would
419 be a reasonable candidate. We hypothesized that OGT contributed to the XX-specific
420 cytosine modifications since this post-translational modification enzyme is an X-linked
421 gene product (Shafi et al., 2000) that interacts with and modifies TETs in mESCs (Vella
422 et al., 2013; Hrit et al., 2018). OGT modification stimulates TET activity (Hrit et al., 2018)
423 and the OGT-TET interaction has been implicated in control of TET nucleocytoplasmic
424 distribution (Zhang et al., 2014) and chromatin association (Ito et al., 2013; Vella et al.,
425 2013; Chen et al. 2013), providing multiple molecular mechanisms by which OGT dose
426 could control abundance of cytosine modifications.

427
428 If OGT dose plays a role in the X-copy number dependent regulation of 5mC and 5hmC,
429 then levels of OGT should differ between XX and XY mESCs. Immunoblot of whole cell
430 lysates revealed that OGT was more abundant in XX than XY mESCs (Fig. 1C),
431 consistent with its expression from two active Xs.

432

433 To determine if OGT dose affects 5mC and 5hmC levels we employed an OGT over-
434 expressing XY mESC line ($XY^{Tg(Ogt)}$) (Vella et al., 2013) (Fig. 1D). Using IF, we found
435 that 5mC and 5hmC levels decrease in the $XY^{Tg(Ogt)}$ mESC line compared to the
436 parental XY mESC (XY^{Par}) line (Fig. 1E, F). Because we were unable to generate
437 heterozygous *Ogt* mutant XX mESCs, which is consistent with the pre-implantation
438 lethality of *Ogt* heterozygous mutants in mice (Shafi et al., 2000), we employed a
439 degron to change OGT dose. We introduced an inducible, FKBP degron (Nabet et al.,
440 2018) into OGT produced from one X, generating two, independently-derived XX
441 WT/OGT-deg clones (Fig. 1G, Fig.1-fig. sup. 1D-E), which died after five days of
442 treatment with dtag13 (dtag) to deplete FKBP-tagged OGT. After 12 hours of treatment
443 with dtag, FKBP-tagged OGT was no longer detectable (Fig. 1H, Fig. 1-fig. sup. 1F) and
444 5mC and 5hmC levels were increased (Fig. 1I-L, Fig.1-fig. sup. 1G-H). This inverse
445 correlation between OGT levels and 5mC/5hmC abundance suggests that OGT, directly
446 or indirectly, controls an enzyme that adds or removes cytosine DNA modifications.

447

448 **OGT differentially modifies TET3 in XX and XY mESCs**

449 Since we investigated the role of OGT in 5mC and 5hmC accumulation because it can
450 regulate TETs, we next asked whether TET O-GlcNAcylation differs in XX and XY
451 mESCs. We employed Stable Isotope Labeling with Amino acids in Culture (SILAC)
452 combined with lectin-weak affinity chromatography to enrich O-GlcNAC peptides and
453 EThcD-MS/MS to quantitatively compare O-GlcNAcylation peptide abundance in XX and
454 XY mESCs (Fig. 2A). TET3 was unique among the TETs because all of its O-GlcNAC
455 peptides were upregulated in XX mESCs relative to XY mESCs (Fig. 2B-D). To
456 determine if this increase indicated a difference in total protein, we compared TET
457 levels in whole cell lysates of XX and XY mESCs and found that TET3, in contrast to
458 TET1 and TET2, was more abundant in XX mESCs (Fig. 2E).

459

460 **OGT and TET3 accumulate in the nucleus of XX mESCs but not in XY mESCs**

461 OGT can control TET3 nucleocytoplasmic distribution (Zhang et al., 2014) prompting us
462 to investigate TET3 distribution in XX and XY mESCs. IF revealed that TET3 was
463 predominantly cytoplasmic in XY mESCs and predominantly nuclear in XX mESCs (Fig.

464 3A). This nuclear accumulation occurred in an additional XX mESC line (PGK12.1) and
465 was not dependent on growth media, as it was observed in mESC media and 2i media
466 (Fig. 3-fig. sup. 1A-B). Immunoblotting for TET3 in nuclear extracts showed that more
467 TET3 was present in XX nuclei than XY nuclei (Fig. 3B), consistent with the IF
468 results. Similarly, OGT was predominantly localized to the nucleus in XX and to the
469 cytoplasm in XY mESCs (Fig. 3C-D).

470
471 OGT and TET3 interact when co-expressed in transformed human cells (Ito et al.,
472 2014). We queried whether XX mESCs also showed this interaction using co-
473 immunoprecipitation (co-IP) and co-fractionation. For co-IP experiments we generated
474 an XX mESC line in which both alleles of *Ogt* were tagged with GFP (Fig 3.-fig. sup. 1C-
475 D). TET3 associated with OGT-GFP in IPs generated with a GFP antibody (Fig.
476 3E). Size exclusion column chromatography of nuclear extracts showed that OGT and
477 TET3 fractionate together in high molecular weight complexes in both XX and XY
478 mESCs (Fig. 3F). However, the fractions containing OGT and TET3 differed between
479 XX and XY mESC nuclear extracts, suggesting that the OGT-TET3 complex
480 composition is affected by the number of Xs and/or the presence of the Y chromosome.

481
482 In addition to OGT, XX, and XY mESCs have the potential to differ in dose of the
483 majority of X-linked genes, any number of which could control TET3 nucleocytoplasmic
484 distribution. To determine whether OGT dose affects TET3 localization we used a time
485 course to assess the effects of OGT turnover on TET3 distribution in XX WT/OGT-deg
486 mESCs. After 12 hours of dtag incubation, TET3 no longer appeared distinctly nuclear.
487 After 48 hours it was observed predominantly in the cytoplasm and there was a
488 decrease in TET3 abundance (Fig. 3G). Like TET3, OGT also appeared to be
489 predominantly cytoplasmic after 48 hours in dtag (Fig. 3G). While dtag-treated XX
490 WT/OGT-deg mESCs exhibited lower levels of OGT by IF, immunoblot showed that
491 after 48 hours of turnover of the OGT-deg the expression of wildtype OGT increased
492 (Fig. 3H, Fig. 3-fig. sup. 1E), potentially reflecting differences in epitope availability in IF
493 and immunoblot. As was observed for 12 hours of dtag treatment, 5mC and 5hmC
494 levels were increased after 48 hours in dtag (Fig. 3I-J). The decrease in TET3

495 observed after 48 hours of dtag treatment may contribute to this increase in abundance
496 of modified cytosines. In XY^{Tg(Ogt)}mESCs the increased OGT dose correlated with
497 increased abundance of TET3 and OGT in the nucleus (Fig. 3- fig. sup. 1F). Together
498 these results indicate that the higher OGT dose in XX mESCs promotes nuclear
499 accumulation of TET3 and OGT.

500

501 **XX mESCs lacking TET3 exhibit increased 5mC and 5hmC levels**

502 We reasoned that XX-specific nuclear enrichment of TET3 may provide the basis for
503 lower levels of 5mC and 5hmC in XX mESCs. To test this hypothesis, we mutated both
504 copies of *Tet3* in XX mESCs (Fig. 4-fig.sup 1-3) generating XX-TET3KO mESCs. The
505 XX-TET3KO mESCs exhibited altered colony morphology, growing in tight colonies that
506 expanded more in the vertical than horizontal direction (Fig 4-fig. sup. 4A). Because
507 mutation of TET1 in XX mESCs changed the abundance of TET2 (Hrit et al., 2018), we
508 first examined whether homozygous mutation of *Tet3* affected steady state levels of the
509 other TETs. In XX-TET3KO mESCs TET3 and TET1 were undetectable, while TET2
510 levels were not appreciably altered (Fig. 4A), indicating that TET3 is necessary for TET1
511 accumulation in XX mESCs. 5mC and 5hmC levels in XX-TET3KO mESCs were
512 elevated relative to XX mESCs and enrichment of 5mC at pericentromeric
513 heterochromatin was not as apparent in XX-TET3KO mESCs (Fig. 4B-E). Upon
514 quantitation of fluorescent intensity, 5mC and 5hmC levels in all three XX-TET3KO
515 clones were significantly greater ($p < 0.001$) than XX mESCs (Fig. 4C and E).

516

517 To obtain a high-resolution view of the effects of *Tet3* mutation, we performed whole
518 genome bisulfite sequencing (WGBS) which simultaneously detects 5mC and 5hmC. In
519 all three XX-TET3KO mESC clones, 5mC+5hmC was globally increased compared to
520 three replicates of XX mESCs (Fig. 4F-G, Fig.4- fig. sup. 5A-B). Differentially modified
521 region (DMR) analysis over 1kb non-overlapping windows tiled genome-wide identified
522 6,741 DMRs, which almost exclusively had more 5mC+5hmC in XX-TET3KOs than XX
523 mESCs (Fig. 4- fig. sup. 6A-B). When comparing the X to autosomes, we observed that
524 DMRs were slightly but consistently depleted from the X and that the X was less
525 modified overall, in both XX and XX-TET3KO mESCs (Fig. 4- fig. sup. 7). While

526 5mC+5hmC were increased on the X in XX-TET3KOs, the increase was less than the
527 increase on autosomes. Analysis of major and minor satellite repeats showed that
528 unlike major satellites in the rest of the genome, minor satellites did not appreciably
529 increase levels of 5mC+5hmC (Fig. 4- fig. sup. 8A-B), consistent with the uniform 5mC
530 staining throughout the nucleus in XX-TET3KO mESCs. Together, these bisulfite-seq
531 and IF results indicate that TET3 and TET1 are necessary to maintain correct levels of
532 5mC+5hmC and correct distribution of 5mC in XX mESCs.

533

534 To ask whether the changes in cytosine modifications observed in XX-TET3KO mESCs
535 impacted gene expression, we performed RNA-seq. 104 genes were up regulated in the
536 XX-TET3KO mESCs relative to XX controls, and 86 were down regulated (Fig. 4H, Fig.
537 4-fig. sup. 4B). Cytosine modification pathway transcripts were not significantly changed
538 in XX-TET3KO mESCs (Fig. 4I). Gene Ontology (GO) term analysis of the 190 genes
539 with altered expression showed no statistically significant results.

540

541 **XX-TET3KO mEpiLCs exhibit altered Xist RNA distribution**

542 XX and XY mESCs are pluripotent and have the potential to differentiate into all cell
543 types of the developing and adult mouse embryo (Reik et al., 2015). To ask whether the
544 XX-specific nuclear enrichment of TET3 is necessary for a developmental transition, we
545 differentiated XX and XX-TET3KO mESCs into mEpiLCs. Both cell types exhibited
546 comparable morphology at day 5 of differentiation (Fig.5- fig. sup.1A). While the
547 differentiating XX-TET3KO mESCs initially grew normally, after day 4 they exhibited
548 more cell death than their wildtype counterparts. Comparison of XX and XX-TET3KO
549 mEpiLC RNA-seq at day 5 of differentiation showed that 404 genes exhibited increased
550 expression and 499 exhibited decreased expression in XX-TET3KO mEpiLCs (Fig. 5A,
551 Fig. 5-fig. sup. 1B). The expression of mESC markers (naive pluripotency genes) went
552 down and mEpiLC markers (formative and/or primed pluripotency genes) went up
553 comparably upon differentiation of XX and XX-TET3KO mESCs (Fig. 5B), suggesting
554 that many key transcriptional changes that characterize this transition can occur when
555 TET3 is knocked out. Despite up-regulation of mEpiLC markers, GO term analysis
556 showed gene expression changes affecting growth and development (Fig. 5C),

557 suggesting an altered developmental program. Upon differentiation, IF showed that
558 5mC and 5hmC in XX-TET3KO mEpiLCs were comparable to XX mEpiLCs (Fig 5-fig.
559 sup. 1C-D), consistent with similar changes in steady state RNA levels of *Dnmts* and
560 *Tets* in both genotypes (Fig. 5-fig. sup. 1E).

561
562 The mESC to mEpiLC transition is similar to the transition that occurs upon implantation
563 *in vivo*, and is accompanied by significant epigenetic changes (Takahashi et al., 2018).
564 One of these changes is XCI, which occurs in XX, but not XY cells. The onset of XCI is
565 marked by the up-regulation and *cis*-spread of the X-linked *Xist* non-coding RNA from
566 its site of transcription to cover, or coat, the X that will be silenced (Boeren et al., 2021).
567 *Xist* is silenced by 5mC/5hmC in differentiating XY mESCs, since the aberrant up-
568 regulation and *cis*-spread of *Xist* RNA occurs in differentiating XY mESCs that have
569 dramatically reduced 5mC/5hmC due to loss of DNMT1 (Panning et al., 1996). This
570 result indicates that the elevated 5mC and/or 5hmC in XY mESCs inhibits the up-
571 regulation and *cis*-spread of *Xist* RNA and raises the possibility that the increase in
572 cytosine modifications in XX-TET3KO mESCs may impact *Xist* RNA. To examine this
573 possibility, we performed *Xist* RNA fluorescence *in situ* hybridization (FISH) in XX and
574 XX-TET3KO mEpiLCs. In XX mEpiLCs, *Xist* RNA was present in puncta packed into
575 spherical clouds typical of coating in the majority of cells (Fig 5. D-E). In XX-TET3KO
576 mEpiLCs *Xist* RNA distribution was markedly different, showing a more dispersed
577 pattern, appearing as a linear or comet-like cloud in the majority of cells (Fig 5. D-
578 E). These results show that TET3 is necessary for normal *Xist* RNA distribution at the
579 onset of XCI.

580
581 *Xist* RNA recruits the Polycomb Repressive Complex 2, which results in an increase in
582 H3K27 tri-methylation (H3K27me3) on the *Xist* RNA coated X (Sarma et al., 2014). To
583 ask whether loss of TET3 alters the ability of *Xist* RNA to promote H3K27me3 we
584 performed *Xist* RNA FISH together with IF for this mark in XX and XX-TET3KO
585 mEpiLCs (Fig. 5F). The *Xist* RNA and H3K27me3 signals overlapped in the majority of
586 cells in both XX (97%) and XX-TET3KO (91%) mEpiLCs (Fig. 5-fig. sup. 1F), indicating
587 that TET3 is not necessary for *Xist* RNA to recruit H3K27me3 enzymes.

588 In differentiated XX cells, Xist RNA is often observed at the nuclear periphery, in
589 contact with the nuclear lamina (Rego et al., 2008). To ask whether the aberrantly
590 distributed Xist RNA in XX-TET3KO mEpiLCs exhibits association with the nuclear
591 lamina, we performed IF for H3K27me3 and the nuclear lamina marker LAMIN B1
592 (LMNB1). In both XX mEpiLCs and in XX-TET3KO the region of H3K27me3 enrichment
593 was localized to the LMNB1-stained nuclear lamina (Fig. 5G) in greater than 85% of the
594 cells (Fig. 5-fig. sup. 1G). In XX-TET3KO mEpiLCs, LMNB1 levels appeared to be
595 lower than in XX cells. LMNB1 transcripts were comparable between genotypes,
596 suggesting any differences on the protein level cannot be attributed to steady state RNA
597 differences (Fig. 5-fig. sup. 1H). These H3K27me3 and LMNB1 data suggest that
598 despite its aberrant distribution, Xist RNA in XX-TET3KO mEpiLCs is able to mediate
599 changes in chromatin structure and nuclear organization that are characteristic of
600 silencing.

601
602 To ask whether Xist RNA was able to cause other chromosome-wide alterations
603 associated with silencing, we examined whether exclusion of RNA polymerase II (pol II)
604 or histone H3 lysine 4 di-methylation (H3K4me2) occurred in XX-TET3KO mEpiLCs.
605 While pol II and H3K4me2 were excluded from the H3K27me3-enriched region in XX
606 mEpiLCs, such exclusion was rarely seen in the XX-TET3KO mEpiLCs (Fig. 6A-D). To
607 determine whether the comet-like Xist RNA coating was able to silence genes, we
608 examined the distribution of COT-1 containing transcripts (Fig. 6E-F). COT-1 consists of
609 repetitive sequences that are present in introns and thus excluded from the inactive X
610 (Hall et al., 2010). FISH for Xist and COT-1 RNA showed that COT-1 containing
611 transcripts were excluded from the Xist RNA cloud in the majority of XX mEpiLCs. In
612 contrast, COT-1 containing transcripts were coincident with Xist RNA in the majority of
613 XX-TET3KO mEpiLCs. Consistent with the silencing defect, a larger proportion of X-
614 linked genes than autosomal genes in the XX-TET3KO mEpiLCs exhibited a 2-fold or
615 greater increase in steady-state RNA levels when compared to XX mEpiLCs (Fig.
616 6G). This analysis of RNA-seq data, in combination with the data showing that the
617 transcriptional machinery, a chromatin mark associated with transcriptional activity, and
618 nascent transcripts are no longer robustly excluded from the Xist RNA or H3K27me3-

619 enriched domain in *Tet3* mutants, indicate that the aberrantly distributed Xist RNA in
620 XX-TET3KO mEpiLCs does not efficiently silence X-linked genes.

621

622 Discussion:

623 **OGT regulates levels of modified cytosines in mESCs**

624 Our results show that OGT dose affects levels of 5mC and 5hmC in mESCs.

625 Specifically, increased expression of OGT in XY mESCs resulted in a decrease in these
626 cytosine modifications, while decreased expression in XX mESCs resulted in an
627 increase in both these modifications. These results implicate OGT as one of the X-
628 linked genes that contributes to the decreased levels of 5mC and 5hmC observed in XX
629 mESCs relative to XY/XO mESCs. The phosphatase DUSP9 is another X-linked
630 regulator of cytosine modifications, since heterozygous deletion of *Dusp9* in XX mESCs
631 increases 5mC levels (Choi et al., 2017). Our data raise the possibility that OGT may be
632 one of the factors that DUSP9 signaling influences to regulate cytosine modifications.

633

634 Since OGT activity is regulated by levels of its cofactor UDP-GlcNAc, the inverse
635 relationship between OGT dose and abundance of cytosine modifications provides a
636 potential connection between the cell's metabolic state and the epigenome. These
637 results raise the interesting possibility that inputs into UDP-GlcNAc production, like
638 glucose and glutamine, may impact gene expression by controlling cytosine
639 modification states. In addition, differences in access to glucose and glutamine within
640 colonies may contribute to the variability in intensity and distribution of 5mC staining in
641 XX mESCs.

642

643 **OGT-modified TET3 is more abundant in XX than XY mESCs**

644 While OGT has thousands of potential targets, our unbiased mass spectrometry
645 approach identified TET3 as a cytosine modification enzyme that is differentially
646 modified by OGT in XX vs XY mESCs. The higher abundance of O-GlcNAcylated TET3
647 peptides in XX mESCs reflected an increase in the total amount of TET3. In addition,
648 TET3 in XX mESCs was largely nuclear, while it was largely cytoplasmic in XY mESCs.
649 The lower abundance and predominantly cytoplasmic localization of TET3 in XY

650 mESCs is consistent with near-undetectable expression of endogenously tagged TET3
651 in this cell type (Pantier et al., 2019) and may explain why TET3 makes a smaller
652 contribution to total 5hmC than TET1 and TET2 in XY mESCs (Dawalaty et al., 2014).
653 Since *de novo* methyltransferases are more abundant in XY mESCs (Zvetcova et al.,
654 2005; Schulz et al., 2014) (Fig 7- fig. sup. 1A) and TET3 resides in the nucleus and is
655 more highly expressed in XX mESCs, the X-copy number dependent differences in
656 5mC/5hmC likely reflect the differing balance between addition and turnover activities in
657 these pluripotent stem cells. Because OGT modifies many additional histone post-
658 translational modification enzymes and chromatin remodelers (Myers et al., 2011), it is
659 possible that the epigenetic differences between XX and XY mESCs are not restricted
660 to cytosine modifications.

661

662 **OGT dose determines intracellular distribution of TET3 and OGT**

663 The XX-specific nuclear accumulation of TET3 and OGT depends on the XX dose of
664 OGT, since turnover of OGT arising from one X results in the redistribution of TET3 and
665 OGT to the cytoplasm (Fig. 7A). TET3 may be preferentially localized in the nucleus
666 due to its increased O-GlcNAcylation in XX mESCs. This post-translational modification
667 could be acting on the sequences necessary for nuclear export or import. The dose-
668 dependent nuclear enrichment of OGT in XX mESCs may be dependent on its
669 association with TET3 or on its O-GlcNAcylation (Kreppel et al., 1997). In contrast to
670 this finding in mESCs, OGT inhibits nuclear accumulation of TET3 when these proteins
671 are co-transfected into HeLa cells (Zhang et al., 2014), raising the possibility that TET3
672 distribution is controlled in a cell-type specific manner. OGT interacts with TET3 and
673 these proteins occur in differing high molecular weight complexes in XX and XY
674 mESCs. Determining what other proteins are in the complexes may give insight as to
675 why OGT and TET3 are localized to the nucleus in XX mESCs.

676

677 **Mutation of *Tet3* affects 5mC/5hmC abundance in XX mESCs**

678 Knockout of TET3 in XX mESCs resulted in loss of TET1 and increased abundance of
679 5mC and 5hmC without notable changes in gene expression. The distribution of these
680 marks was similar between XX and XX-TET3KO mESCs, with an overall increase in the

681 non-repetitive regions of the mutant genomes. The X exhibited lower modifications than
682 autosomes in both genotypes, though the difference was less marked in the XX-
683 TET3KOs. Allele-specific analysis would be necessary to determine if one or both Xs is
684 the source of the overall reduction in 5mC+5hmC relative to autosomes. In addition the
685 heterogeneity of 5mC staining was reduced and enrichment of 5mC at pericentromeric
686 heterochromatin was less marked in XX-TET3KO mESCs. Because both TET3 and
687 TET1 are no longer appreciably detectable in the XX-TET3KO mESCs, it is impossible
688 to distinguish which enzyme to attribute particular changes in 5mC and 5hmC to. TET1
689 steady state mRNA levels are not appreciably altered in XX-TET3KO mESCs,
690 suggesting post-transcriptional regulation of TET1 accumulation. In XX mESCs, a
691 mutation in TET1 that impairs its interaction with OGT results in increased abundance of
692 TET2 without a change in *Tet2* mRNA levels (Hrit et al., 2018). Understanding how the
693 abundance of all three TETs is connected, and if this connection is unique to pluripotent
694 cells with two Xs, may provide useful insights into TET biology.

695

696 **XX-TET3KO mEpiLCs exhibit changes in Xist RNA distribution and silencing**

697 In XX and XX-TET3KO mEpiLCS naive pluripotency markers were decreased and
698 formative/primed pluripotency markers were increased, indicating that both genotypes
699 achieved key hallmarks of differentiation into mEpiLCs. Despite similar changes in
700 pluripotency marker expression, XX and XX-TET3KO mEpiLCs exhibited expression
701 differences in growth and developmental pathways, consistent developmental failure
702 observed upon germline deletion of TET3, TET1, or all three TETs (Gu et al., 2011; Dai
703 et al., 2016; Khoueiry et al., 2017).

704

705 While achieving hallmarks of mEpiLC differentiation, distribution and activity of Xist RNA
706 was altered in XX-TET3KO mEpiLCs. A spherical Xist RNA cloud was predominantly
707 seen in wildtype XX mEpiLCs, while an elongated comet-like cloud was seen most often
708 in XX-TET3KO mEpiLCs. Despite this unusual distribution, H3K27me3 was enriched
709 where Xist RNA localizes and the region of H3K27me3-enrichment, presumably
710 reflecting the Xist coated X, associates with the nuclear lamina. In wildtype mEpiLCs,
711 regions of H3K27me3 enrichment or Xist RNA accumulation are associated with

712 silencing, as shown by exclusion of pol II, H3K4me2, and nascent transcripts. In
713 contrast, these three indicators of transcriptional activity are not excluded in XX-
714 TET3KO mEpiLCs (Fig. 7B-C).

715
716 XCI is coupled to differentiation, since normal differentiation of XX mESCs to mEpiLCs
717 requires XCI (Schulz et al., 2014). In addition, Xist RNA can coat but not silence the X in
718 XY mESCs expressing an inducible Xist cDNA transgene if expression is induced after
719 2 days of embryoid body or retinoic acid-induced differentiation (Wutz et al. 2000).
720 Together, these findings suggest that there is a precise developmental window during
721 which the X is silencing competent, and that a silencing-induced signal in XX mESCs is
722 necessary for further differentiation. Perhaps the changes in the proteome or
723 epigenome associated with differentiation occur with different kinetics when XX-
724 TET3KO mESCs are directed to the mEpiLC fate, affecting one or both of these
725 processes.

726
727 Mutational analysis of *Xist* revealed that Initial establishment of silencing during XCI
728 involves at least two steps: the formation of a compartment that contains Xist RNA and
729 that is devoid of transcriptional machinery, followed by the shift of transcriptionally active
730 genes into this silencing compartment. (Wutz et al., 2002; Chaumeil et al., 2006). A
731 repetitive region of Xist, the E-repeat, is necessary for formation of the Xist RNA-
732 containing silencing compartment. The E-repeat nucleates a protein condensate that is
733 critical for silencing, by virtue of its interaction with the RNA binding protein CELF1 and
734 associated proteins (Pandya-Jones et al., 2020). Xist RNA in mEpiLCs derived from
735 *Tet3* mutant mESCs exhibits similarities to E-repeat mutant Xist RNA, which also shows
736 an altered distribution and silencing defects (Pandya-Jones et al., 2020). The similarity
737 between the *Tet3* mutant and *Xist E-repeat* mutant phenotypes may indicate that both
738 perturbations affect the same pathway. While expression of proteins associated with
739 Xist RNA mediated silencing is not significantly altered in XX-TET3KO mESCs (Fig. 7-
740 fig. sup. 1B), perhaps a protein that is necessary for CELF1 complex activity is
741 aberrantly expressed or exhibits altered function in differentiating XX-TET3KO

742 mESCs. Alternatively, epigenetic changes to the underlying chromatin may make the X
743 in differentiating XX-TET3KO mESCs an unsuitable substrate for silencing.

744

745 **Does the OGT-TET3 complex ensure silencing occurs only in XX cells?**

746 In flies and worms, which also equalize X-linked gene dosage between the sexes, the
747 dosage compensation pathway is controlled by complexes that are sensitive to the ratio
748 of X to autosomal components (Cline et al., 1996). The activities of these complexes
749 differ when the X:autosome ratio is 1:1 (XX) or 0.5:1 (XY in flies or XO in worms). As a
750 result, a two-fold difference in X-linked components can be converted into an all-or-none
751 response and the expression of the factors that mediate dosage compensation depends
752 on X dosage. Our data suggest that the OGT-TET3 complex may participate in
753 mammalian X-dosage sensing, since it differs in distribution and composition in XX and
754 XY mESCs and since TET3 is necessary for Xist RNA-mediated silencing.

755

756 Acknowledgements:

757 We thank the Vella Lab for the XY^{Par} and XY^{Tg(Ogt)} mESC lines. We thank the Genomics
758 High Throughput Facility Shared Resource of the Cancer Center Support Grant
759 (P30CA-062203) at the University of California, Irvine and NIH shared instrumentation
760 grants 1S10RR025496-01, 1S10OD010794-01, and 1S10OD021718-01 for RNA-seq
761 library preparation, sequencing, and data analysis. We thank Mahnaz Akhavan and
762 the Broad Stem Cell Research Center BioSequencing Core for high throughput
763 sequencing. We thank all members of the Panning lab, Elphege Nora, Vijay Ramani,
764 and Kate Carbone for valuable ideas and discussion. This work was supported by R01
765 GM128431-02 (BP), F32 GM136115 (CLP), the Sandler Program for Breakthrough
766 Biomedical Research (BP) (AB), the Dr Miriam & Sheldon G. Adelson Medical Research
767 Foundation (AB), the Howard Hughes Medical Institute (AB) (SEJ).

768

769 Competing Interests:

770 There are no financial or non-financial competing interests on behalf of all authors.

771

772

773 References:

774 Baker, P. R., & Chalkley, R. J. (2014). MS-viewer: A web-based spectral viewer for
775 proteomics results. *Molecular & Cellular Proteomics: MCP*, 13(5), 1392–1396.

776 <https://doi.org/10.1074/mcp.O113.037200>

777

778 Baker, P. R., Trinidad, J. C., & Chalkley, R. J. (2011). Modification site localization
779 scoring integrated into a search engine. *Molecular & Cellular Proteomics: MCP*, 10(7),

780 M111.008078. <https://doi.org/10.1074/mcp.M111.008078>

781

782 Bauer, C., Göbel, K., Nagaraj, N., Colantuoni, C., Wang, M., Müller, U., Kremmer, E.,
783 Rottach, A., & Leonhardt, H. (2015). Phosphorylation of TET Proteins Is Regulated via
784 O-GlcNAcylation by the O-Linked N-Acetylglucosamine Transferase (OGT). *The Journal*
785 *of Biological Chemistry*, 290(8), 4801–4812. <https://doi.org/10.1074/jbc.M114.605881>

786

787 Benjamini Y, Hochberg Y. (1995) Controlling the False Discovery Rate: A Practical and
788 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B*
789 *(Methodological)*, 57(1), 289-300.

790

791 Boeren, J., & Gribnau, J. (2021). Xist-mediated chromatin changes that establish
792 silencing of an entire X chromosome in mammals. *Current Opinion in Cell Biology*, 70,
793 44–50. <https://doi.org/10.1016/j.ceb.2020.11.004>

794

795 Chaumeil, J., Le Baccon, P., Wutz, A., & Heard, E. (2006). A novel role for Xist RNA in
796 the formation of a repressive nuclear compartment into which genes are recruited when
797 silenced. *Genes & Development*, 20(16), 2223–2237.

798 <https://doi.org/10.1101/gad.380906>

799

800

801 Chen, Q., Chen, Y., Bian, C., Fujiki, R., & Yu, X. (2013). TET2 promotes histone O-
802 GlcNAcylation during gene transcription. *Nature*, 493(7433), 561–564.

803 <https://doi.org/10.1038/nature11742>

804

805 Choi, J., Clement, K., Huebner, A. J., Webster, J., Rose, C. M., Brumbaugh, J., Walsh,
806 R. M., Lee, S., Savol, A., Etchegaray, J.-P., Gu, H., Boyle, P., Elling, U., Mostoslavsky,
807 R., Sadreyev, R., Park, P. J., Gygi, S. P., Meissner, A., & Hochedlinger, K. (2017).
808 DUSP9 Modulates DNA Hypomethylation in Female Mouse Pluripotent Stem Cells. *Cell*
809 *Stem Cell*, 20(5), 706-719.e7. <https://doi.org/10.1016/j.stem.2017.03.002>

810

811 Cline, T. W., & Meyer, B. J. (1996). Vive la différence: Males vs females in flies vs
812 worms. *Annual Review of Genetics*, 30, 637–702.
813 <https://doi.org/10.1146/annurev.genet.30.1.637>

814

815 Dai, H.-Q., Wang, B.-A., Yang, L., Chen, J.-J., Zhu, G.-C., Sun, M.-L., Ge, H., Wang, R.,
816 Chapman, D. L., Tang, F., Sun, X., & Xu, G.-L. (2016). TET-mediated DNA
817 demethylation controls gastrulation by regulating Lefty-Nodal signalling. *Nature*,
818 538(7626), 528–532. <https://doi.org/10.1038/nature20095>

819

820 Dawlaty, M. M., Breiling, A., Le, T., Barrasa, M. I., Raddatz, G., Gao, Q., Powell, B. E.,
821 Cheng, A. W., Faull, K. F., Lyko, F., & Jaenisch, R. (2014). Loss of Tet enzymes
822 compromises proper differentiation of embryonic stem cells. *Developmental Cell*, 29(1),
823 102–111. <https://doi.org/10.1016/j.devcel.2014.03.003>

824

825 Driegen, S., Ferreira, R., van Zon, A., Strouboulis, J., Jaegle, M., Grosveld, F.,
826 Philipsen, S., & Meijer, D. (2005). A generic tool for biotinylation of tagged proteins in
827 transgenic mice. *Transgenic Research*, 14(4), 477–482. <https://doi.org/10.1007/s11248-005-7220-2>

829

830 Gu, T.-P., Guo, F., Yang, H., Wu, H.-P., Xu, G.-F., Liu, W., Xie, Z.-G., Shi, L., He, X.,
831 Jin, S., Iqbal, K., Shi, Y. G., Deng, Z., Szabó, P. E., Pfeifer, G. P., Li, J., & Xu, G.-L.
832 (2011). The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes.
833 *Nature*, 477(7366), 606–610. <https://doi.org/10.1038/nature10443>

834

- 835 Habibi, E., Brinkman, A. B., Arand, J., Kroeze, L. I., Kerstens, H. H. D., Matarese, F.,
836 Lepikhov, K., Gut, M., Brun-Heath, I., Hubner, N. C., Benedetti, R., Altucci, L., Jansen,
837 J. H., Walter, J., Gut, I. G., Marks, H., & Stunnenberg, H. G. (2013). Whole-Genome
838 Bisulfite Sequencing of Two Distinct Interconvertible DNA Methylomes of Mouse
839 Embryonic Stem Cells. *Cell Stem Cell*, 13(3), 360–369.
840 <https://doi.org/10.1016/j.stem.2013.06.002>
841
- 842 Halim, A., Westerlind, U., Pett, C., Schorlemer, M., Rüetschi, U., Brinkmalm, G.,
843 Sihlbom, C., Lengqvist, J., Larson, G., & Nilsson, J. (2014). Assignment of Saccharide
844 Identities through Analysis of Oxonium Ion Fragmentation Profiles in LC–MS/MS of
845 Glycopeptides. *Journal of Proteome Research*, 13(12), 6024–6032.
846 <https://doi.org/10.1021/pr500898r>
847
- 848 Hall, L. L., & Lawrence, J. B. (2010). XIST RNA and Architecture of the Inactive X
849 chromosome: Implications for the Repeat Genome. *Cold Spring Harbor Symposia on*
850 *Quantitative Biology*, 75, 345–356. <https://doi.org/10.1101/sqb.2010.75.030>
851
- 852 Hrit, J., Goodrich, L., Li, C., Wang, B.-A., Nie, J., Cui, X., Martin, E. A., Simental, E.,
853 Fernandez, J., Liu, M. Y., Nery, J. R., Castanon, R., Kohli, R. M., Tretyakova, N., He,
854 C., Ecker, J. R., Goll, M., & Panning, B. (2018). OGT binds a conserved C-terminal
855 domain of TET1 to regulate TET1 activity and function in development. *ELife*, 7,
856 e34870. <https://doi.org/10.7554/eLife.34870>
857
- 858 Ito, R., Katsura, S., Shimada, H., Tsuchiya, H., Hada, M., Okumura, T., Sugawara, A., &
859 Yokoyama, A. (2014). TET3-OGT interaction increases the stability and the presence of
860 OGT in chromatin. *Genes to Cells: Devoted to Molecular & Cellular Mechanisms*, 19(1),
861 52–65. <https://doi.org/10.1111/gtc.12107>
862
- 863 Khoueiry, R., Sohni, A., Thienpont, B., Luo, X., Velde, J. V., Bartocchetti, M., Boeckx, B.,
864 Zwijsen, A., Rao, A., Lambrechts, D., & Koh, K. P. (2017). Lineage-specific functions of

- 865 TET1 in the postimplantation mouse embryo. *Nature Genetics*, 49(7), 1061–1072.
866 <https://doi.org/10.1038/ng.3868>
867
- 868 Kohlmaier, A., Savarese, F., Lachner, M., Martens, J., Jenuwein, T., & Wutz, A. (2004).
869 A Chromosomal Memory Triggered by Xist Regulates Histone Methylation in X
870 Inactivation. *PLOS Biology*, 2(7), e171. <https://doi.org/10.1371/journal.pbio.0020171>
871
- 872 Kreppel, L. K., Blomberg, M. A., & Hart, G. W. (1997). Dynamic Glycosylation of Nuclear
873 and Cytosolic Proteins: CLONING AND CHARACTERIZATION OF A UNIQUE O-
874 GlcNAc TRANSFERASE WITH MULTIPLE TETRATRICOPEPTIDE REPEATS *.
875 *Journal of Biological Chemistry*, 272(14), 9308–9315.
876 <https://doi.org/10.1074/jbc.272.14.9308>
877
- 878 Krueger, F. (2021). *FelixKrueger/TrimGalore* [Perl].
879 <https://github.com/FelixKrueger/TrimGalore> (Original work published 2016)
880
- 881 Krueger, F., & Andrews, S. R. (2011). BKrueger, F. (2021). *FelixKrueger/TrimGalore*
882 [Perl]. <https://github.com/FelixKrueger/TrimGalore> (Original work published 2016)
883
- 884 Lewis, B. A., & Hanover, J. A. (2014). O-GlcNAc and the Epigenetic Regulation of Gene
885 Expression. *The Journal of Biological Chemistry*, 289(50), 34440–34448.
886 <https://doi.org/10.1074/jbc.R114.595439>
887
- 888 Maynard, J., & Chalkley, R. J. (2020). Methods for Enrichment and Assignment of N-
889 Acetylglucosamine Modification Sites. *Molecular & Cellular Proteomics: MCP*, 20,
890 100031. <https://doi.org/10.1074/mcp.R120.002206>
891
- 892 Mlynarczyk-Evans, S., Royce-Tolland, M., Alexander, M. K., Andersen, A. A., Kalantry,
893 S., Gribnau, J., & Panning, B. (2006). X Chromosomes Alternate between Two States
894 prior to Random X-Inactivation. *PLoS Biology*, 4(6).
895 <https://doi.org/10.1371/journal.pbio.0040159>

- 896 Myers, S. A., Panning, B., & Burlingame, A. L. (2011). Polycomb repressive complex 2
897 is necessary for the normal site-specific O-GlcNAc distribution in mouse embryonic
898 stem cells. *Proceedings of the National Academy of Sciences*, 108(23), 9490–9495.
899 <https://doi.org/10.1073/pnas.1019289108>.
900
- 901 Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A.
902 L., Erb, M. A., Lawlor, M. A., Souza, A., Scott, T. G., Vittori, S., Perry, J. A., Qi, J.,
903 Winter, G. E., Wong, K.-K., Gray, N. S., & Bradner, J. E. (2018). The dTAG system for
904 immediate and target-specific protein degradation. *Nature Chemical Biology*, 14(5),
905 431–441. <https://doi.org/10.1038/s41589-018-0021-8>
906
- 907 Pandya-Jones, A., Markaki, Y., Serizay, J., Chitiashvili, T., Mancina, W., Damianov, A.,
908 Chronis, C., Papp, B., Chen, C.-K., McKee, R., Wang, X.-J., Chau, A., Sabri, S.,
909 Leonhardt, H., Zheng, S., Guttman, M., Black, Douglas. L., & Plath, K. (2020). A protein
910 assembly mediates Xist localization and gene silencing. *Nature*, 587(7832), 145–151.
911 <https://doi.org/10.1038/s41586-020-2703-0>
912
- 913 Panning, B., & Jaenisch, R. (1996). DNA hypomethylation can activate Xist expression
914 and silence X-linked genes. *Genes & Development*, 10(16), 1991–2002.
915 <https://doi.org/10.1101/gad.10.16.1991>
916
- 917 Pantier, R., Tatar, T., Colby, D., & Chambers, I. (2019). Endogenous epitope-tagging of
918 Tet1, Tet2 and Tet3 identifies TET2 as a naïve pluripotency marker. *Life Science*
919 *Alliance*, 2(5). <https://doi.org/10.26508/lsa.201900516>
920
- 921 Parry, A., Rulands, S., & Reik, W. (2021). Active turnover of DNA methylation during
922 cell fate decisions. *Nature Reviews Genetics*, 22(1), 59–66.
923 <https://doi.org/10.1038/s41576-020-00287-8>
924
- 925 Pignatta, D., Bell, G. W., & Gehring, M. (2015). Whole Genome Bisulfite Sequencing
926 and DNA Methylation Analysis from Plant Tissue. *Bio-Protocol*, 5(4), e1407–e1407.

- 927 Plath, K., Mlynarczyk-Evans, S., Nusinow, D. A., & Panning, B. (2002). Xist RNA and
928 the Mechanism of X Chromosome Inactivation. *Annual Review of Genetics*, 36(1), 233–
929 278. <https://doi.org/10.1146/annurev.genet.36.042902.092433>
930
- 931 Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013).
932 Genome engineering using the CRISPR-Cas9 system. *Nature Protocols*, 8(11), 2281–
933 2308. <https://doi.org/10.1038/nprot.2013.143>
934
- 935 Rego, A., Sinclair, P. B., Tao, W., Kireev, I., & Belmont, A. S. (2008). The facultative
936 heterochromatin of the inactive X chromosome has a distinctive condensed
937 ultrastructure. *Journal of Cell Science*, 121(Pt 7), 1119–1127.
938 <https://doi.org/10.1242/jcs.026104>
939
- 940 Reik, W., & Surani, M. A. (2015). Germline and Pluripotent Stem Cells. *Cold Spring*
941 *Harbor Perspectives in Biology*, 7(11). <https://doi.org/10.1101/cshperspect.a019422>
942 Ross, S. E., & Bogdanovic, O. (2019). TET enzymes, DNA demethylation and
943 pluripotency. *Biochemical Society Transactions*, 47(3), 875–885.
944 <https://doi.org/10.1042/BST20180606>
945
- 946 R Core Team. (2017). R: A language and environment for statistical computing. R
947 Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>
948
- 949 Sarma, K., Cifuentes-Rojas, C., Ergun, A., del Rosario, A., Jeon, Y., White, F.,
950 Sadreyev, R., & Lee, J. T. (2014). ATRX Directs Binding of PRC2 to Xist RNA and
951 Polycomb Targets. *Cell*, 159(4), 869–883. <https://doi.org/10.1016/j.cell.2014.10.019>
952
- 953 Schulz, E. G., Meisig, J., Nakamura, T., Okamoto, I., Sieber, A., Picard, C., Borensztein,
954 M., Saitou, M., Blüthgen, N., & Heard, E. (2014). The Two Active X Chromosomes in
955 Female ESCs Block Exit from the Pluripotent State by Modulating the ESC Signaling
956 Network. *Cell Stem Cell*, 14(2), 203–216. <https://doi.org/10.1016/j.stem.2013.11.022>
957

- 958 Seo, H. G., Kim, H. B., Kang, M. J., Ryum, J. H., Yi, E. C., & Cho, J. W. (2016).
959 Identification of the nuclear localisation signal of O -GlcNAc transferase and its nuclear
960 import regulation. *Scientific Reports*, 6(1), 34614. <https://doi.org/10.1038/srep34614>
961
- 962 Shafi, R., Iyer, S. P. N., Ellies, L. G., O'Donnell, N., Marek, K. W., Chui, D., Hart, G. W.,
963 & Marth, J. D. (2000). The O-GlcNAc transferase gene resides on the X chromosome
964 and is essential for embryonic stem cell viability and mouse ontogeny. *Proceedings of*
965 *the National Academy of Sciences*, 97(11), 5735–5739.
966 <https://doi.org/10.1073/pnas.100471497>
967
- 968 Shi, F.-T., Kim, H., Lu, W., He, Q., Liu, D., Goodell, M. A., Wan, M., & Songyang, Z.
969 (2013). Ten-Eleven Translocation 1 (Tet1) Is Regulated by O-Linked N-
970 Acetylglucosamine Transferase (Ogt) for Target Gene Repression in Mouse Embryonic
971 Stem Cells. *The Journal of Biological Chemistry*, 288(29), 20776–20784.
972 <https://doi.org/10.1074/jbc.M113.460386>
973
- 974 Smit A, Hubley R, Green P. (1996) *RepeatMasker Open-3.0*,
975 <http://www.repeatmasker.org/>
976
- 977 Song, J., Janiszewski, A., De Geest, N., Vanheer, L., Talon, I., El Bakkali, M., Oh, T., &
978 Pasque, V. (2019). X-Chromosome Dosage Modulates Multiple Molecular and Cellular
979 Properties of Mouse Pluripotent Stem Cells Independently of Global DNA Methylation
980 Levels. *Stem Cell Reports*, 12(2), 333–350.
981 <https://doi.org/10.1016/j.stemcr.2018.12.004>
982
- 983 Takahashi, S., Kobayashi, S., & Hiratani, I. (2018). Epigenetic differences between
984 naïve and primed pluripotent stem cells. *Cellular and Molecular Life Sciences*, 75(7),
985 1191–1203. <https://doi.org/10.1007/s00018-017-2703-x>
986
- 987 Trinidad, J. C., Barkan, D. T., Gulledge, B. F., Thalhammer, A., Sali, A., Schoepfer, R.,
988 & Burlingame, A. L. (2012). Global Identification and Characterization of Both O-

989 GlcNAcylation and Phosphorylation at the Murine Synapse. *Molecular & Cellular*
990 *Proteomics : MCP*, 11(8), 215–229. <https://doi.org/10.1074/mcp.O112.018366>
991
992 von Meyenn, F., Iurlaro, M., Habibi, E., Liu, N. Q., Salehzadeh-Yazdi, A., Santos, F.,
993 Petrini, E., Milagre, I., Yu, M., Xie, Z., Kroeze, L. I., Nesterova, T. B., Jansen, J. H., Xie,
994 H., He, C., Reik, W., & Stunnenberg, H. G. (2016). Impairment of DNA Methylation
995 Maintenance Is the Main Cause of Global Demethylation in Naive Embryonic Stem
996 Cells. *Molecular Cell*, 62(6), 848–861. <https://doi.org/10.1016/j.molcel.2016.04.025>
997
998 Wickham H. (2016) *Ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New
999 York; <https://ggplot2.tidyverse.org>
1000
1001 Wijchers, P. J., Geeven, G., Eyres, M., Bergsma, A. J., Janssen, M., Verstegen, M.,
1002 Zhu, Y., Schell, Y., Vermeulen, C., Wit, E. de, & Laat, W. de. (2015). Characterization
1003 and dynamics of pericentromere-associated domains in mice. *Genome Research*.
1004 <https://doi.org/10.1101/gr.186643.114>
1005
1006 Wutz, A., & Jaenisch, R. (2000). A Shift from Reversible to Irreversible X Inactivation Is
1007 Triggered during ES Cell Differentiation. *Molecular Cell*, 5(4), 695–705.
1008 [https://doi.org/10.1016/S1097-2765\(00\)80248-8](https://doi.org/10.1016/S1097-2765(00)80248-8)
1009
1010 Wutz, A., Rasmussen, T. P., & Jaenisch, R. (2002). Chromosomal silencing and
1011 localization are mediated by different domains of Xist RNA. *Nature Genetics*, 30(2),
1012 167–174. <https://doi.org/10.1038/ng820>
1013
1014 Xiao, P., Zhou, X., Zhang, H., Xiong, K., Teng, Y., Huang, X., Cao, R., Wang, Y., & Liu,
1015 H. (2013). Characterization of the nuclear localization signal of the mouse TET3 protein.
1016 *Biochemical and Biophysical Research Communications*, 439(3), 373–377.
1017 <https://doi.org/10.1016/j.bbrc.2013.08.075>
1018

1019 Zhang, Q., Liu, X., Gao, W., Li, P., Hou, J., Li, J., & Wong, J. (2014). Differential
1020 Regulation of the Ten-Eleven Translocation (TET) Family of Dioxygenases by O-Linked
1021 β -N-Acetylglucosamine Transferase (OGT). *The Journal of Biological Chemistry*,
1022 289(9), 5986–5996. <https://doi.org/10.1074/jbc.M113.524140>
1023
1024 Zvetkova, I., Apedaile, A., Ramsahoye, B., Mermoud, J. E., Crompton, L. A., John, R.,
1025 Feil, R., & Brockdorff, N. (2005). Global hypomethylation of the genome in XX
1026 embryonic stem cells. *Nature Genetics*, 37(11), 1274–1279.
1027 <https://doi.org/10.1038/ng1663>
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038




Figure 1. OGT dose controls cytosine modifications in mESCs. (A-B) IF staining of XX, XY, and XO mESCs using (A) 5mC and (B) 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. 5mC staining in XX mESCs is heterogeneous, with some cells exhibiting enrichment at pericentromeric heterochromatin (*) and some showing no apparent enrichment (arrowhead). (C-D) OGT and TUBULIN immunoblots of increasing concentration of whole cell lysate to compare OGT levels in (C) XX and XY mESCs and (D) parental XY (XY^{Par}) and XY^{Tg(Ogt)} mESCs. * indicates transgenic FLAG-Bio tagged OGT. (E-F) IF of XY^{Par} and XY^{Tg(Ogt)} mESCs using (E) 5mC and (F) 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. (G) Diagram of OGT degron (OGT-deg) strategy in XX mESCs. OGT-deg arising from the tagged *Ogt* allele is turned over by the addition of dtag. (H) OGT and TUBULIN immunoblot of XX WT/OGT-deg mESCs. * indicates degron tagged OGT. +dtag indicates a 12-hour incubation with dtag. (I and K) IF of XX WT/OGT-deg mESCs with or without 12-hour dtag incubation using (I) 5mC and (K) 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. (J and L) Quantitation of fluorescence intensity for (I) 5mC and (K) 5hmC staining in two XX WT/OGT-deg clones treated with dtag for 0 and 12 hours, n=50 over three replicates for each condition. *p<0.001. Scale bars in all merged images indicate 5μM.




Figure 1- figure supplement 1. (A-B) IF of XX and XY mESCs grown in 2i using (B) 5mC and (C) 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. (C) Proportion of XX mESC cells exhibiting enriched pericentromeric heterochromatin staining of 5mC, $n > 100$. Error bars indicate sd. (D) Schematic of XX WT/OGT-deg genotype. DNA encoding the FKBP degron (deg) was added to the 3' end of one *Ogt* allele, followed by a 2A sequence and green fluorescent protein sequence (GFP). The 2A sequence causes ribosome skipping, resulting in separate translation of OGT-deg and 2A-GFP. Orange line: template used for homology-directed repair (HDR). Horizontal arrows: primers used for PCR genotyping. (E) PCR genotyping of two independently derived, and targeted XX mESC clones using primers indicated in (D). (F) OGT and TUBULIN (TUB) immunoblot of second, independently-derived clone of XX WT/OGT-deg and XX WT/WT mESCs. In WT/OGT-deg cells the lower band represents OGT arising from the wild type allele and the larger band (*) is consistent with the anticipated 13 kDa increase introduced by the degron tag. +dtag indicates a 12-hour incubation with dtag. (G and H) IF of second, independently-derived XX WT/OGT-deg clone with or without 12-hour dtag incubation using (G) 5mC and (H) 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. White scale bars in all merged images indicate 5 μ m.




Figure 2. O-GlcNAc-modified TET3 peptides are more abundant in XX mESCs than XY mESCs. (A) Schematic of proteomic workflow: XX and XY mESCs were grown in heavy and light isotope media, respectively, and combined. Tryptic digests of combined samples were subject to lectin weak affinity chromatography (LWAC) to enrich for O-GlcNAcylated peptides. EThcD-MS/MS identified peptides and O-GlcNAc sites. (B) Table of fold change (log2) of XX/XY for each specific serine or threonine O-GlcNAc site found for TET1, TET2, and TET3. O-GlcNAc sites not previously identified (Bauer et al., 2015) are bolded. (C) Diagram of mouse TET proteins, yellow star indicates O-GlcNAc site, blue box indicates CXXC domain, yellow box indicates catalytic domain, purple box indicates TET3 nuclear localization signal, KKRK (Xiao et al., 2013). (D) The spectrum of TET3 O-GlcNAcylated at T1278. (E) TET1, TET2, TET3, and TUBULIN (TUB) immunoblots of increasing concentration of whole cell lysate prepared from XX and XY mESCs.




Figure 3. OGT and TET3 accumulate in the nucleus of XX but not XY mESCs. (A) IF of TET3 (green) in XX and XY mESCs. DAPI (blue) indicates nuclei. (B) TET3 and histone H3 (H3) immunoblots of increasing concentration of nuclear lysate prepared from XX and XY mESCs. (C) IF of OGT (red) in XX and XY mESCs. DAPI (blue) indicates nuclei. (D) OGT and SOX2 immunoblots of increasing concentration of nuclear lysate prepared from XX and XY mESCs. (E) OGT tagged with GFP (endogenously on both Xs); XX-OGT-GFP was immunoprecipitated with a GFP monoclonal antibody. Immunoblots show input and IP probed with TET3 and GFP monoclonal antibody. (F) OGT and TET3 immunoblots of fractions from size exclusion chromatography of nuclear extracts prepared from XX and XY mESCs. Size of molecular weight markers indicated by arrows. (G) IF of TET3 (green) and OGT (red) in (G) XX WT/OGT-deg mESCs with or without 12hr and 48hr dtag incubation. DAPI (blue) indicates nuclei. (H) OGT and TUBULIN immunoblot of XX WT/OGT-deg mESCs. * indicates degron tagged OGT. +dtag indicates 48-hour incubation. (I) IF of XX WT/OGT-deg mESCs with or without 48-hour dtag incubation using 5mC and 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. (J) Quantitation of fluorescence intensity for 5mC and 5hmC staining in two XX WT/OGT-deg clones treated with or without dtag for 48 hours, n=50 over three replicates for each condition. *p<0.001. Scale bars in all merged images indicate 5μM.




Figure 3- figure supplement 1. (A) IF for TET3 (green) in XX mESCs grown in 2i media. DAPI (blue) indicates nuclei, White star indicates mESC in mitosis. (B) IF of TET3 (green) in PGK12.1, a second XX mESC line. DAPI (blue) indicates nuclei. (C) Schematic of XX-*Ogt*^{gfp/gfp} genotype. DNA encoding a 17 amino acid flexible linker and green fluorescent protein (GFP) was added to the 3'end of both *Ogt* alleles. Orange line: template used for homology-directed repair (HDR). Horizontal arrows: primers used for PCR genotyping. (D) PCR genotyping of two independently derived, and targeted mESC clones using primers indicated in (C). (E) OGT and TUBULIN (TUB) immunoblot of XX WT/WT mESCs and a second independently-derived clone of XX WT/OGT-deg. In WT/OGT-deg cells the lower band represents OGT arising from the wild type allele and the larger band (*) is consistent with the anticipated 13 kDa increase introduced by the degron tag. +dtag indicates a 48-hour incubation with dtag. (F) IF of TET3 (green) and OGT (red) in XY^{Par} and XY^{Tg(Ogt)} mESCs. DAPI (blue) indicates nuclei. Scale bars in all merged images indicate 5 μ m.




Figure 4. Loss of TET3 alters cytosine modifications without significantly changing gene expression in XX mESCs. (A) TET1-3 and TUBULIN (TUB) immunoblots of whole cell lysate from wildtype (XX) and 3 independently-derived TET3 knock-out (XX-TET3KO) XX mESCs. TET3 antibody is directed to a C-terminal epitope which is downstream of the guide cut sites that lie in the first coding exon. (B and D) IF of (B) 5mC (green in Merge) and (D) 5hmC (green in Merge) in XX and XX-TET3KO 1 mESCs. DAPI (blue in Merge) indicates nuclei. Scale bars in all merged images indicate 5 μ m. (C and E) Fluorescence quantitation of (B) 5mC and (D) 5hmC staining in XX and XX-TET3KO clones. * indicates statistically significant difference, $p < 0.001$. Error bars indicate sd, $n = 50$ over three replicates for each condition. (F) Difference in WGBS average CG methylation percentage between one XX replicate (rep) and the remaining samples, over 1kb regions tiled genome-wide. (G) Smoothed scatterplot of average methylation over 1kb bins tiling the entire genome in XX (x-axis) vs. XX-TET3KO 1 (y-axis). Line of best fit indicated by black dotted line, with corresponding equation and R^2 value at top of each plot. $y = x$ line plotted in grey for reference. (H) Volcano plot of RNA-seq data from XX versus XX-TET3KO clones showing genes with fold changes (\log_2) > -4 and < 4 . 3 genes are excluded. Red dots indicate genes with fold changes (\log_2) < -1 or > 1 and adjusted p-value < 0.01 . (I) Table of fold change (\log_2) and adjusted p-value ($-\log_{10}$) of cytosine modification enzymes in XX versus XX-TET3KO mESC clones.

A

Table 1. Mismatches and indels of XX-TET3KO sequences adjacent to PAM. Red indicates mismatches and indels. Blue indicates final G (C on strand shown) of the PAM

Cell line	allele	mm10: 83380143-83380107
XX	1 st / 2 nd	CACCTAGTCCCTCCGGGGACAGCCTGCTGCCCCCTA
XX-TET3KO 1	1 st	CACCTAGTCCC--CGGGGACAGCCTGCTGCCCCCTA
XX-TET3KO 1	2 nd	CACCTAGTCCC--CGGGGACAGCCTGCTGCCCCCTA
XX-TET3KO 2	1 st	CACCTAGTCCC--CGGGGACAGCCTGCTGCCCCCTA
XX-TET3KO 2	2 nd	CACCTAGTCCC--CGGGGACAGCCTGCTGCCCCCTA
XX-TET3KO 3	1 st	CACCTAGTCCC--CGGGGACAGCCTGCTGCCCCCTA
XX-TET3KO 3	2 nd	CACCTAGTCCC--CGGGGACAGCCTGCTGCCCCCTA

B

Table 2. Additional mismatches and indels in mm10: 83380835-833380134

XX-TET3KO	allele	Additional mismatches/indels
1	1 st	0
1	2 nd	1 (83380335 C->A)
2	1 st	0
2	2 nd	24 (see sequence on figure 4- figure supplement 2)
3	1 st	0
3	2 nd	5 (see sequence on figure 4- figure supplement 3)

Figure 4- figure supplement 1. (A) Table 1 of mismatches and indels of XX-TET3KO sequences adjacent to PAM. Red font indicates mismatches and indels. Blue font indicates final G (C on strand shown) of PAM. Mm10 refers to the NCBI GRC38 *Mus. musculus* genome. (B) Table 2 of additional mismatches and indels within the PAM regions.

XX-TET3KO 2, 2nd allele sequence matching mm10/GRCm39 chr 6:83380844-83380134

Query strand: XX-Tet3KO 2 sequence

Sbjct strand: mm10/GRCM39 sequence

C: Final G (C on this sequence) of PAM site

-/base pair: Mismatches and indels

```

TET3-KO2-2      CAGGAGACACCCCGAAACTCCTGGCCTGTACCTCcccca
                |||
Sbjct  83380844  CAGGACACCCCG-GAACTCCTGGCCTGTACCTCGCCCA  83380805

TET3-KO2-2      agccctgaccctatGGCAAACCTGGAACATTATTGGGCAGCGCCAGTGATTACTCCAG
                |||
Sbjct  83380804  AGCCCTGACCCTATGGCAGAACTGGAAGCAGCTATTGGGCAGCGCCAGTGATTACTCCAG  83380745

TET3-KO2-2      TCAGTATTCAAGCGGCCTGAGGCCCTGCCACCAAGCCCAAGGTCAAGGTTGAGgcccc
                |||
Sbjct  83380744  TCAGTATTCAAGCGGCCTGAGGCCCTGCCACCAAGCCCAAGGTCAAGGTTGAGGCCCC  83380685

TET3-KO2-2      tcttcttcccctgCTCCGGTACCATCTCCTATTTCTCAAGGGAGGCTCCCCTGCTGTCT
                |||
Sbjct  83380684  TCTTCTTCCCCTGCTCCGGTACCATCTCCTATTTCTCAGAGGGAGGCTCCCCTGCTGTCT  83380625

TET3-KO2-2      TCAAGCCTGACACCCACCAAAGGCCCAACAGCCCTTCAGCAACATCTTCATCACAAG
                |||
Sbjct  83380624  TCAAGCCTGACACCCACCAAGGCCCAACAGCCCTTCAGCAACATCTTCATCACAAG  83380565

TET3-KO2-2      CGCAACCTATTCTTGAACAGGCCCAAGATGCCTCCTTCCCTACTTCCACAGAGCCTCAG
                |||
Sbjct  83380564  CGCAACCTATTCTTGAACAGGCCCAAGATGCCTCCTTCCCTACTTCCACAGAGCCTCAG  83380505

TET3-KO2-2      GCTCCTGGTTGGGGGCCCTCCCGGTCACCTGCCCAAGGCCTCTGACAAACCacc
                |||
Sbjct  83380504  GCTCCTGGTTGGGGGCCCTCCCGGTCACCTGCCCAAGGCCTCTGACAAACCACC  83380445

TET3-KO2-2      aaggaaaagaaaaagaagccccCACCCTGCTGGAGGTCCCGTGGGAGCAAAGAAAACC
                |||
Sbjct  83380444  AAGGAAAAGAAAAGAAGCCCCCACCCTGCTGGAGGTCCCGTGGGAGCAGAGAAAACC  83380385

TET3-KO2-2      ATCCCTGGGATCAAGACCAGTGTCCGAAAGCCATTAGATCAAGAAATCCAGGTCCAGG
                |||
Sbjct  83380384  ACCCTGGGATCAAGACCAGTGTCCGAAAGCCATTAGATCAAGAAATCCAGGTCCAGG  83380325

TET3-KO2-2      GACATGCAGCCCTCTTCTGCCTGTTAGGCAGATTGTTCTGGAAGGGCTAACCCCAA
                |||
Sbjct  83380324  GACATGCAGCCCTCTTCTGCCTGTTAGGCAGATTGTTCTGGAAGGGCTAAACCCCAA  83380265

TET3-KO2-2      GCCTCAGAAGGACAGGCACCGTTACCCCGTCCATCTCTCTGTCCACCTCCTGCCTCCA
                |||
Sbjct  83380264  GCCTCAGAAGGACAGGCACCGTTACCCGCTCCAGCTCTCTCTGTCCACCTCCTGCCTCCA  83380206

TET3-KO2-2      GGGAGCTGCATCCAGAGCTGTGCCACCCCTTAACCCCAAACTTCTCTTGGCGTATT
                |||
Sbjct  83380205  GGGTGTGCATCCAGAGCTGTGCCACCCCTTAACCCCAAACTTCTCTTGGCGTATT  83380146

TET3-KO2-2      TGCACCTAGTCC
                |||
Sbjct  83380145  TGCACCTAGTCC  83380134
    
```

Figure 4- figure supplement 2. Aligned sequences of XX-TET3KO alleles to mm10/GRCm39 genome. Query strand indicates XX-TET3KO PCR product using FW and REV primers 40 base pairs up or downstream of the PAM site. Sbjct strand indicates the mm10/GRCm39 *mus musculus* genome. Blue text and highlight indicates the final G (C on strand) of the PAM site. Red text and yellow highlight indicate mismatches and indels between the PAM sites.

XX-TET3KO 3, 2nd allele sequence matching mm10/GRCm39 chr 6:83380844-833800134

Sbjct strand: mm10/GRCM39 sequence

C: Final G (C on this sequence) of PAM site

-/base pair: Mismatches and indels

```

TET3-KO3-2      CAGGCGACACCCCGGAACCTCTGGCCTGTACCTCgccaagccctgacc
                |
Sbjct  83380844 CAGGCGACACCCCGGAACCTCTGGCCTGTACCTCGCCCAAGCCCTGACC 83380795

TET3-KO2-2      ctatGGCAGAACTGGAGCAGCTATTGGGCAGCGCCAGTGATTACATCCAGTCAGTATTCA
                |||
Sbjct  83380794 CTATGGCAGAACTGGAGCAGCTATTGGGCAGCGCCAGTGATTACATCCAGTCAGTATTCA 83380735

TET3-KO2-2      AGCGGCCTGAGGCCCTGCCACCAAGCCCAAGGTCAAGGTTGAGgccccctcttcttccc
                |||
Sbjct  83380734 AGCGGCCTGAGGCCCTGCCACCAAGCCCAAGGTCAAGGTTGAGGCCCTCTTCTTCCC 83380675

TET3-KO2-2      ctgCTCCGTTACCATCTCTATTTCTCAAGGGAGGCTCCCCTGCTGTCTTCAGAGCCTG
                |||
Sbjct  83380674 CTGCTCCGTTACCATCTCTATTTCTCAAGGGAGGCTCCCCTGCTGTCTTCAGAGCCTG 83380615

TET3-KO2-2      ACACCCACCATAAGGCCCAGACAGCCCTTCACCAACATCTTCATCACAAGCGCAACCTAT
                |||
Sbjct  83380614 ACACCCACCAGAAGGCCCAGACAGCCCTTCAGCAACATCTTCATCACAAGCGCAACCTAT 83380555

TET3-KO2-2      TCTTGGAACAGGCCCAAGATGCCTCCTTCCCTACTTCCACAGAGCCTCAGGCTCCTGGTT
                |||
Sbjct  83380554 TCTTGGAACAGGCCCAAGATGCCTCCTTCCCTACTTCCACAGAGCCTCAGGCTCCTGGTT 83380495

TET3-KO2-2      GGTGGGCCCTCCCGGCTCACCTGCCCAAGGCCTCTGACAAACCaccaaggaaaaga
                |||
Sbjct  83380494 GGTGGGCCCTCCCGGCTCACCTGCCCAAGGCCTCTGACAAACCACCAAGGAAAAGA 83380435

TET3-KO2-2      aaaagaagccccCACCCCTGCTGGAGGTCCCGTGGGAGCAGAGAAAACCACCCCTGGGA
                |||
Sbjct  83380434 AAAAGAAGCCCCCACCCCTGCTGGAGGTCCCGTGGGAGCAGAGAAAACCACCCCTGGGA 83380375

TET3-KO2-2      TCAAGACCAGTGTCCGAAAGCCATTCAGATCAAGAAATCCAGGTCCAGGGACATGCAGC
                |||
Sbjct  83380374 TCAAGACCAGTGTCCGAAAGCCATTCAGATCAAGAAATCCAGGTCCAGGGACATGCAGC 83380315

TET3-KO2-2      CCCTCTTCCTGCCTGTTAGGCAGATTGTTCTGGAAGGGCTAAAACCCCAAGCCTCAGAAG
                |||
Sbjct  83380314 CCCTCTTCCTGCCTGTTAGGCAGATTGTTCTGGAAGGGCTAAAACCCCAAGCCTCAGAAG 83380255

TET3-KO2-2      GACAGGCACCGTTACCCGCCAGCTCTCTGTCCCACCTCCTGCCTCCCAGGGTGCTGCAT
                |||
Sbjct  83380254 GACAGGCACCGTTACCCGCCAGCTCTCTGTCCCACCTCCTGCCTCCCAGGGTGCTGCAT 83380195

TET3-KO2-2      CCCAGAGCTGTGCCACTCTCTAACCCAGAACCTTCTCTTGCGCTATTTGCACCTAGTC
                |||
Sbjct  83380194 CCCAGAGCTGTGCCACCCTCTAACCCAGAACCTTCTCTTGCGCTATTTGCACCTAGTC 83380135

TET3-KO2-2      C
                |
Sbjct  83380134 C 83380134
    
```

Figure 4- figure supplement 3. Aligned sequences of XX-TET3KO alleles to mm10/GRCm39 genome. Query strand indicates XX-TET3KO PCR product using FW and REV primers 40 base pairs up or downstream of the PAM site. Sbjct strand indicates the mm10/GRCm39 *mus musculus* genome. Blue text and highlight indicates the final G (C on strand) of the PAM site. Red text and yellow highlight indicate mismatches and indels between the PAM sites.




Figure 4- figure supplement 4 (A) Brightfield images of XX and XX-TET3KO mESCs grown in ESC or 2i media. In contrast to the normal colony morphology of XX mESCs, XX-TET3KO mESCs exhibit towering colonies which grow vertically regardless of media type. White scale bars indicates 5 μ M. (B) Full volcano plot comparing RNA-seq from XX and XX-TET3KO mESCs showing genes excluded in Fig. 4H. Red dots indicate genes with fold changes (\log_2) < -1 or > 1 and adjusted p-value < 0.01.




Figure 4- figure supplement 5. WGBS of XX-TET3KO versus XX mESCs. (A) Smoothed scatterplot of average methylation over 1kb bins tiling the entire genome in XX (x-axis) vs. XX-TET3KO (y-axis). Line of best fit indicated by black dotted line, with equation and R^2 value at top of each plot. $y=x$ line also plotted in grey for reference. Scale from 0-100 (%CG methylation) (B) Example region on ChrX showing hypermethylation in XX-TET3KO lines relative to XX.




Figure 4- figure supplement 6. DMR analysis of XX-TET3KO WGBS data. (A) Percent of all informative 1kb windows tiled genome-wide that were identified as significant DMRs for each set of comparisons. Plots on left show XX vs. XX-TET3KO, plots on right show within-genotype (false positive) DMRs. (B) Distribution of the 6,741 ‘consensus’ XX < XX-TET3KO DMRs (identified as DMRs in at least 5/9 pairwise comparisons between all XX and XX-TET3KO replicates), relative to other common genomic features: transposons, protein-coding genes, and pericentromere associated domains (Wijchers et al. 2015). Plots show loess-smoothed average feature density (number of features) or feature coverage (average % of bp covered by feature) for 50kb windows tiled genome-wide. First six autosomes + X shown.





Figure 5- figure supplement 7. Loess-smoothed average CG (top) and non-CG (bottom) methylation (5mC + 5hmC) over chromosomes 1, 2, and X. Methylation was averaged over 50kb windows.






Figure 5. Loss of TET3 alters gene expression and Xist RNA distribution in mEpiLCs. (A) Volcano plot of RNA-seq data from XX versus XX-TET3KO mEpiLC clones showing genes with fold changes (log₂) > -7 and < 7 and adjusted p-value (-log₁₀) > 60. Red dots indicate genes with fold changes (log₂) < -1 or > 1 and adjusted p-value (-log₁₀) < 0.01. (B) Fold change (log₂) between day 0 and day 5 of differentiation for selected naïve and formative/primed pluripotency markers in XX (light purple) and XX-TET3KO (dark purple) cells. (C) GO terms (biological process) enriched for genes differentially expressed between XX and XX-TET3KO mEpiLCs. Only GO terms with FDR p-values < 0.01 are included. n indicates the number of differentially expressed genes in the data set/the number of genes that define that GO term. (D) The predominant pattern of Xist RNA FISH (red) in XX and XX-TET3KO 1 at day 5 of mEpiLC differentiation. DAPI (blue) indicates nuclei. (E) Proportion of cells exhibiting different Xist RNA distribution patterns in XX and XX-TET3KO 1 mEpiLCs, n > 100 cells/replicate. (F) Xist RNA FISH (red in Merge) combined with IF for H3K27me3 (green in Merge) in XX and XX-TET3KO 1 mEpiLCs. DAPI (blue in Merge) indicates nuclei. The white box indicates the location of the zoom-in for each image. For quantitation see Fig. 5- fig. sup. 1F. (G) IF of H3K27me3 (green in Merge) and LAMIN B1 (LMNB1; red in Merge) in XX and XX-TET3KO 1 mEpiLCs. DAPI (blue in Merge) indicates nuclei. For quantitation see Fig. 5- fig. sup. 1G. White scale bar in all merged images indicates 5µm.




Figure 5- figure supplement 1. (A) Representative brightfield images of Day 5 mEpiLC differentiation in XX and XX-TET3KO cells. XX-TET3KO mEpiLCs exhibit considerably more cell death beginning day 4 of differentiation. A larger number of XX-TET3KO mEpiLCs were plated in order to visualize cell morphology in this image. (B) Full volcano plot comparing RNA-seq from XX and XX-TET3KO mEpiLCs showing genes excluded in Fig. 5A. Red dots indicate genes with fold changes (log₂) < -1 or > 1 and adjusted p-value (-log₁₀) < 0.01. (C-D) IF of XX and XX-TET3KO 1 mEpiLCs using (C) 5mC and (D) 5hmC antibodies (green in Merge). DAPI (blue in Merge) indicates nuclei. White scale bar (Merge) indicates 5µm. (E) Table of fold change (log₂) and adjusted p-values (-log₁₀) of cytosine modification enzymes in XX/XX-TET3KO mEpiLCs. (F) Proportion of cells exhibiting H3K27me₃ enrichment associated with Xist RNA in XX and XX-TET3KO mEpiLCs, n>100 cells/replicate. (G) Proportion of nuclei exhibiting H3K27me₃ overlap with LMNB1 staining. Error bars indicate sd, n>100 cells/replicate. (H) Fold change (log₂) of lamin-associated transcripts from XX mEpiLC/XX-TET3KO mEpiLC RNA-seq.




Figure 6. Xist RNA function is disrupted in XX-TET3KO mEpiLCs. (A) IF of RNA polymerase II (pol II; red in Merge) and H3K27me3 (green in Merge) in XX and XX-TET3KO 1 mEpiLCs. DAPI (blue in Merge) indicates nuclei. The white box indicates the location of the zoom-in for each image. (B) Proportion of nuclei exhibiting pol II exclusion for XX and XX-TET3KO clones. Error bars indicate sd, $n > 100$ cells/replicate. (C) IF of H3K4me2 (red in Merge) and H3K27me3 (green in Merge) in XX and XX-TET3KO 1 mEpiLCs. DAPI (blue in Merge) indicates nuclei. (D) Proportion of cells exhibiting H3K4me2 exclusion in XX and XX-TET3KO clones. Error bars indicate sd, $n > 100$ cells/replicate. (E) Xist RNA FISH (red in Merge) combined with COT1 RNA FISH (green in Merge) in XX and XX-TET3KO 1 mEpiLCs. DAPI (blue in Merge) indicates nuclei. (F) Proportion of cells exhibiting exclusion of COT1 RNA in Xist RNA-enriched regions. Error bars indicate sd, $n > 100$ /replicate. White scale bars in all merged images indicate 5 μ m. (G) The proportion of genes with a fold change (\log_2) of < -1 (dark purple) or > 1 (light purple), $\text{padj}(\log -10) < 0.01$ in XX mEpiLCs vs XX-TET3KO mEpiLCs, normalized to the total number of expressed genes per chromosome.




Figure 7. TET3 exhibits X-dose dependent distribution in mESCs and is necessary for Xist RNA-mediated silencing upon differentiation. (A) TET3 is enriched in the nucleus in XX mESCs and enriched in cytoplasm of mESCs that express OGT from one X (XY and XX WT/OGT-deg mESCs). (B) Xist RNA is distributed in a spherical, cloud-like shape and H3K27me3 is enriched in the same region (red) while pol II, H3K4me2, and nascent transcripts are excluded from that region (green) in wildtype XX mEpiLCs. In the XX-TET3KO mEpiLC clones, Xist RNA is distributed in a linear, comet-like shape, which is coincident with H3K27me3 enrichment, from which pol II, H3K4me2, and nascent transcripts are not excluded. Yellow indicates the overlap between Xist RNA/H3K27me3 (red) and pol II/H3K4me2/nascent transcripts (green). (C) TET3 is necessary Xist RNA mediated silencing, as measured by exclusion of pol II, H3K4me2, and nascent transcripts.




Figure 7- figure supplement 1 (A) DNMT1, DNMT3A, DNMT3B, and SOX2 immunoblots of increasing concentration of whole cell lysate prepared from XX and XY mESCs. (B) Table of fold change (log2) and adjusted p-values (-log10) of XIC-associated genes, comparing XX and XX-TET3KO mEpiLCs.

A

Cell Line Name	Sex	Origin
LF2	XX	
Pgk12.1	XX	
E14	XY	
LF2-XO	XO	Panning Lab
XY ^{Par}	XY	XYRosa26 ^{HABirA/+} (Driegen et al., 2005)
XY ^{Tg(Ogt)}	XY	Pasini Lab (Vella et al., 2013)
XX WT/OGT-deg	XX- LF2	HDR CRISPR
XX-OGT-GFP	XX- LF2	HDR CRISPR
XX-TET3KO 1-3	XX- LF2	NHEJ CRISPR

B

Cell Line	Guide RNA Sequence 5'-3'
XX WT/OGT-deg	ATGGGATGCTTAATGTGGA
XX-OGT-GFP	ATGGGATGCTTAATGTGGA
XX-TET3KO	CCAGCGACACCCCGGAACTC
XX-TET3KO	CGGAGGGACTAGGTGCAAAT

C

Antibody	Manufacturer	Catalog Number
5mC	Active Motif	39649
5hmC	Active Motif	39791
OGT	Cell Signaling	24083S
TET1	EMD Millipore	MABE1144
TET2	EMD Millipore	MABE462
TET3	Novus Biological	NBP2-20602
TUB	Sigma	T6074
SOX2	Abcam	ab97959
H3	Abcam	ab1791
GFP	Takara	632380
H3K27me3	Invitrogen	MA5-11198
LMNB1	Santa Cruz	sc-374015
pol II	Active Motif	61984
H3K4me2	Active Motif	39079
DNMT1	Cell Signaling	D63A6
DNMT3A	Cell Signaling	2160S
DNMT3B	Abcam	ab16049

Supplemental methods 1. (A) Table of cell lines used and derived for experiments. (B) Table of guide RNA templates used for CRISPR/Cas9 gene editing. (C) Table of primary antibodies used for IF, immunoblots, and co-IPs.

A

XX-OGT WT/deg gene block
TCGGTCTGGTGTGAGTTTCTGATTTGTAATTTGGTTCTCTTTGTTTTACACACCTAGCCTG
AAGAAAATTCGTGGCAAAGTCTGGAACAGAGAATATCTAGCCCTCTGTTCAACACCAAAACAAT
ACACAATGGAATTAGAGCGACTTTATCTGCAGATGTGGGAGCATATGACAGCTGGCAACAAACC
TGACCACATGATTAAGCCTGTGAAGTCAACGAGTCAGCCGGAGTgcaggtggaaccatctcc
ccaggagacggcgcaacttcccaagcggcagacctgcctggtgcactacaccgggatgc
ttgaagatggaaaagaagtgtattccctcccgggacagaaaacaagcccttaagtttatgcttagg
caagcaggaggtgatccgaggctgggaagaagggttgcccagatgagtggtgcagagagcc
aaactgactatctccagattatgctatggtgccactgggcaccaccagccatcatcccaccac
atgccactctcgtcttctgatgtggagcttctaaaactggaa**GGAAGCGAGAGGGCAGAGGAAG**
TCTGCTAACATGCCGTGACGTCGAGGAGAATCCTGGACCTatggtgagcaaggcggcagggagctg
ttaccggggtggtgccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcg
tccggcgagggcgagggcgatgccaccaacggcaagctgaccctgaagttcatctgcaaccac
cggcaagctgcccgtgcccggcccaccctcgtgaccaccttcggtacggcgtggcctgctc
agccgtaccceggaccaatgaagcagcagcagcttctcaagtccgccatgccggaaggctacg
tccaggagcggccaccatctcttcaaggagcagcggtaacctacaagaccggcggcggaggtgaa
cggagggcgacaccctggtgaaccgcatcgagctgaagggtacgacttcaaggaggacggcaac
atcctggggcacaagctggagtacaacttcaacagccacaacgtctatatcaaggccgacaagc
agaagaacggcatcaaggtaacttcaagatccgccacaacgttgaggacggcagcgtgcaact
cgccgaccactaccagcagaacaccccactcggcgacggcccctgctgctgcccgacaaccac
tacctgagccatcagtcgcccctgagcaaaagaccccacgagaagcgcgatcacatggtcctgc
tggagttcgtgaccgcccgggattacacatggcattggacgagctgtacaagtaaTGAATAAA
GACTGCGCACAGGAGAATTCCTTATACCTGAGCCTCAACCTTCTGGGGGAAGGGAAGTATGATA
ACATGCTTTGTGTATCTGTGTAGTTCTGTGTGCAGACGGATGATATATAATGATAATAGAA
TAGCACATTCAGACTTACTTCCTGCATGATAGGGAGAGACAAGAAAAGAAAATGCTATTCCAC
AAGGAATCTCTTAGAGTTTTGCAGCAACAGGTGGTGCACAGTCTGGAAGTCTGGTCTCCCT
TGGTCTTCC**ATGGGATGCTTAATGTGGAGG**aAGATAGAGATTAACCGCCGTTTTGTGATGacG
TGGATTGATCAAGTCTTCTGATCCtttttttttcttttatattttggggtttgagctttttaa
AATGTTTGCCTTCAGGTATTTTACTCATGTGAAGTGATCTTGATCTTCTGAGGTTTTAACT
AAAATGTTGCTTCTGTTTTAGTGTCTGAA

XXX=FKBP
XXX=2A
XXX=GFP
XXX=Guide RNA with PAM site mutated (G>A)

B

XX-OGT-GFP gene block
GCATTATGCAGCTGGCAACAAACCTGACCACATGATTAAGCCTGTGAAAGTCAACGAGTCAGCC
TGA**ttgggggggggggggagcggggggggggggagcgggggggggggggagcgggagc**atggtg
gcaagggcgaggagctgttcaaccggggtggtgccatcctggtcgagctggacggcgacgtaaa
cggccacaagttcagcgtccggcgagggcgagggcgatgccaccaacggcaagctgaccctg
aagttcatctgcaccaccggcaagctgcccgtgcccggcccaccctcgtgaccaccttcggt
acggcgtggcctgcttcagccgctaccocgaccacatgaagcagcagcactcttcaagtccg
catgcccaaggctacgtccaggagcgcaccatctcttcaaggacgacggtaacctacaagacc
cggcccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaaggcctcagct
tcaaggaggacggcaacatcctggggcacaagctggagtacaacttcaacagccacaacgctca
tatcaccggccgacaagcagaagaacggcatcaaggtaacttcaagatccgccacaacggttag
gacggcagcgtgcagctcggcaccactaccagcagaacaccccactcggcgacggcccctg
tctgcccacaaccactacctgagccatcagtcggcctgagcaagaccaccaacgagaagcg
cgatacaatggtcctgctggagttcctgaccggccgggattacaacatggaatggagagctg
tacaagataaagactgcccacaggagaattgcctatacctgagcctcaacctctgggggaa
ggaactagataacatgctttgtgtgtatctgtgtagttctgtgttgcagacggatgatataaa
tgataatagaatagcacattcagacttacttctgcatgatagggagacagaagaagaagaaa
tgcattccacaaggaatctcttagagttttcagcacaacaggtggtgcacaggtctggaaggt
ctggtctcccttggctctcc**atgggatgcttaatgtggagga**gagatagagattaccagcct
ttgtgatgccgtggattgatcaagctctctgatccttttttttttttttttttttttttttt
ggagcttttaaaaatggttgccttcaggtattttttactcatgtgaagtgatcttggat

XXX=17aa linker
XXX=GFP
XXX=Guide RNA with PAM site mutated (G>A)

Supplemental methods 2. (A) Gene block of HDR insert for XX-OGT WT/deg cell line. (B) Gene block of HDR insert for XX-OGT-GFP cell line.

Assay	Amplicon and Purpose	Primer Name	Sequence 5'-3'
RNA FISH	Xist ex1-pooled	ex1-5a	GTCCATGGACAAGTAAACAAAGAAC
		ex1-5b	TATGAGGGTATGGGATCTTGTTA
		ex1-6a	GATCCCATACCCTCATACCCTAAT
		ex1-6b	CTTGAAGGACCATTGACCGTATT
		ex1-7a	TGCTTTATGGAATTATGTATGTGC
		ex1-7b	GGTCCGAAAAGTAATAAGGTTGTG
		ex1-8a	ACTTTTCGGACCATTGTATCTCTT
		ex1-8b	GAGAGCAGGTCATTCGTCAGAG
		ex1-9a	TCCCCTGCTAGTTTCCCAATGT
		ex1-9b	TTTCCACAGACTCATCACCCCTCAG
		ex1-10a	TTTTAAAAGGTGACTGGATGGTT
		ex1-10b	TGATGTAACGGAGGAGCAGTAG
XX-TET3KO genotyping	targeted region of Tet3 exon 3	FW	AGCAACCCCAAGACCTGAGT
XX-TET3KO genotyping	targeted region of Tet3 exon 3	REV	GGGGATCTCATTTCCTGAG
XX WT/OGT-deg	gene block amplification	FW	TCGGTCTGGTCTGAGTTTTCT
XX WT/OGT-deg	gene block amplification	REV	TGCTTCCTGTTTTAGTGTCTGA
XX-OGT-GFP	gene block amplification	FW	GCATTATGCAGCTGGCAACAAA
XX-OGT-GFP	gene block amplification	REV	CTCATGTGAAGTGATCTTCATTC
XX-OGT-GFP	PCR genotyping	FW	CACAATGGAATTAGAGCGACTTT
XX-OGT-GFP	PCR genotyping	REV	TCAGACACTAAAACAGGAAGCAA
XX WT/OGT-deg	PCR genotyping	F#1	TGGTCATATTTTGCCACAGAA
XX WT/OGT-deg	PCR genotyping	R#1	CATCTTCAAGCATCCCGGTG
XX WT/OGT-deg	PCR genotyping	F#2	ATGCCACTCTCGTCTTCGAT
XX WT/OGT-deg	PCR genotyping	R#2	TACACCAGCAAGGTCCTGT

Supplemental methods 3. Table of primers used for creating the Xist RNA FISH probe, XX-TET3KO genotyping, XX WT/OGT-deg gene block amplification/PCR genotyping, and XX-OGT-GFP gene block amplification/PCR genotyping.

Acetyl (Protein N-term)	HexNAc4Hex6 (N) - Rare - Motif 0 N [^] P][ST]
Acetyl+Oxidation (Protein N-term M)	HexNAc4Hex6Fuc (N) - Rare - Motif 0 N [^] P][ST]
Gln->pyro-Glu (N-term Q)	HexNAc4Hex6Fuc2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc4Hex6SA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc (ST)	HexNAc4Hex6SAOx2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc4Hex7 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex3 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex3Fuc (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex (ST) - Rare	HexNAc5Hex3FucSA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex10 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex4 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex2 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex4Fuc (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex2 (ST) - Rare	HexNAc5Hex4Fuc2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex2Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex4FucSA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex3 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex4NeuAc (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex3Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex4SA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex4 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex5 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex4Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex5Fuc (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex5 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex5FucSA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex5Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex5FucSA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex6 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex5SA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex6Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex5SA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex7 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex8 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6Fuc (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2Hex9 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6FucSA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc2HexFuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6FucSA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex3 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6SA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex3Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6SA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex4 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc5Hex6SA3 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex4SA (N) - Rare - Motif 0 N [^] P][ST]	HexNAc6Hex7FucSA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex5 (N) - Rare - Motif 0 N [^] P][ST]	HexNAc6Hex7SA (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex5Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc6Hex7SA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex5SA (N) - Rare - Motif 0 N [^] P][ST]	HexNAc7Hex6SA2 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex5SAOxSAOxAc (N) - Rare - Motif 0 N [^] P][ST]	HexNAc7Hex6SA3 (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex6 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcFuc (N) - Rare - Motif 0 N [^] P][ST]
HexNAc3Hex6Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAcFuc (ST) - Rare
HexNAc3Hex6SA (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHex (ST) - Rare
HexNAc3Hex6SA2 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexFuc (ST) - Rare
HexNAc3Hex7 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSA (ST) - Rare
HexNAc3Hex7Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSA2 (ST) - Rare
HexNAc4Hex3 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAAc (ST) - Rare
HexNAc4Hex3Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAAc2 (ST) - Rare
HexNAc4Hex4 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAAcSAOxAc (ST) - Rare
HexNAc4Hex4Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAOx (ST) - Rare
HexNAc4Hex4Fuc2 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAOx2 (ST) - Rare
HexNAc4Hex4FucSA (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAOxAc2 (ST) - Rare
HexNAc4Hex4SA (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSAOxSAOxAc (ST) - Rare
HexNAc4Hex5 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSASAAc (ST) - Rare
HexNAc4Hex5Fuc (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSASAOx (ST) - Rare
HexNAc4Hex5Fuc2 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcHexSASAOxAc (ST) - Rare
HexNAc4Hex5FucSA (N) - Rare - Motif 0 N [^] P][ST]	HexNAcSA (ST) - Rare
HexNAc4Hex5FucSA2 (N) - Rare - Motif 0 N [^] P][ST]	HexNAcSAOx (ST) - Rare
HexNAc4Hex5FucSAOx2 (N) - Rare - Motif 0 N [^] P][ST]	Label:13C(6) (R) - Label 1
HexNAc4Hex5SA (N) - Rare - Motif 0 N [^] P][ST]	Label:13C(6)15N(2) (K) - Label 1
HexNAc4Hex5SA2 (N) - Rare - Motif 0 N [^] P][ST]	Met-loss (Protein N-term M)
HexNAc4Hex5SAOx (N) - Rare - Motif 0 N [^] P][ST]	Met-loss+Acetyl (Protein N-term M)
HexNAc4Hex5SAOx2 (N) - Rare - Motif 0 N [^] P][ST]	Oxidation (M)
HexNAc4Hex5SAOx3 (N) - Rare - Motif 0 N [^] P][ST]	Pyro-carbamidomethyl (N-term C)
HexNAc4Hex5SAOxSAOxAc (N) - Rare - Motif 0 N [^] P][ST]	

Supplemental methods 4. Table of variable modifications used in the mass spectrometry analysis.

sample	total	% QCpass	% unique	% pass stevefilt	% post dedup	useable read pairs
XX rep 1	356588852	99.33%	65.22%	64.87%	51.11%	182257912
XX rep 2	309181649	98.08%	65.59%	65.17%	52.72%	163011079
XX rep 3	282382403	98.87%	66.32%	65.78%	53.33%	150602628
XX-TET3KO 1	308902389	98.28%	64.03%	63.36%	50.53%	156102714
XX-TET3KO 2	302714581	97.21%	62.06%	61.65%	48.49%	146781146
XX-TET3KO 3	287882797	97.62%	65.34%	65.00%	53.12%	152934556

Supplemental methods 5. Table of Alignment statistics for WGBS libraries. Total = total number of read pairs obtained; % QCpass = percent of total remaining after QC filtering by trim_galore; % unique = percent of total that passed previous filters and aligned uniquely to mm10; % pass stevefilt = percent of total that passed previous filters and passed conversion filter (see methods); % post dedup = percent of total that passed previous filters and remained after PCR duplicates were removed; useable read pairs = final count of read pairs passing all filters that were used for downstream analyses.